<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.5.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art550.dtd?><?SourceDTD.Version 5.5.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_CHOM2009 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEgr4 jpg ?><?FILEgr5 jpg ?><?FILEgr6 jpg ?><?FILEgr7 jpg ?><?FILEfx1 jpg ?><?FILEmmc1 pdf ?><?FILEmmc2 xlsx ?><?FILEmmc3 xlsx ?><?FILEmmc4 pdf ?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Host Microbe</journal-id><journal-id journal-id-type="iso-abbrev">Cell Host Microbe</journal-id><journal-title-group><journal-title>Cell Host &#x00026; Microbe</journal-title></journal-title-group><issn pub-type="ppub">1931-3128</issn><issn pub-type="epub">1934-6069</issn><publisher><publisher-name>Cell Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">S1931-3128(18)30599-7</article-id><article-id pub-id-type="doi">10.1016/j.chom.2018.12.001</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bricault</surname><given-names>Christine A.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="fn1" ref-type="fn">17</xref></contrib><contrib contrib-type="author"><name><surname>Yusim</surname><given-names>Karina</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="fn1" ref-type="fn">17</xref></contrib><contrib contrib-type="author"><name><surname>Seaman</surname><given-names>Michael S.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Yoon</surname><given-names>Hyejin</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Theiler</surname><given-names>James</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Giorgi</surname><given-names>Elena E.</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Wagh</surname><given-names>Kshitij</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Theiler</surname><given-names>Maxwell</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Hraber</surname><given-names>Peter</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Macke</surname><given-names>Jennifer P.</given-names></name><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Kreider</surname><given-names>Edward F.</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Learn</surname><given-names>Gerald H.</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Hahn</surname><given-names>Beatrice H.</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Scheid</surname><given-names>Johannes F.</given-names></name><xref rid="aff5" ref-type="aff">5</xref><xref rid="aff6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Kovacs</surname><given-names>James M.</given-names></name><xref rid="aff7" ref-type="aff">7</xref><xref rid="aff8" ref-type="aff">8</xref><xref rid="aff9" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name><surname>Shields</surname><given-names>Jennifer L.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Lavine</surname><given-names>Christy L.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Ghantous</surname><given-names>Fadi</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Rist</surname><given-names>Michael</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Bayne</surname><given-names>Madeleine G.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Neubauer</surname><given-names>George H.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>McMahan</surname><given-names>Katherine</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>Hanqin</given-names></name><xref rid="aff7" ref-type="aff">7</xref><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name><surname>Ch&#x000e9;neau</surname><given-names>Coraline</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Jennifer J.</given-names></name><xref rid="aff10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name><surname>Zeng</surname><given-names>Jie</given-names></name><xref rid="aff10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name><surname>Ochsenbauer</surname><given-names>Christina</given-names></name><xref rid="aff10" ref-type="aff">10</xref></contrib><contrib contrib-type="author"><name><surname>Nkolola</surname><given-names>Joseph P.</given-names></name><xref rid="aff1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Stephenson</surname><given-names>Kathryn E.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff11" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Bing</given-names></name><xref rid="aff7" ref-type="aff">7</xref><xref rid="aff8" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name><surname>Gnanakaran</surname><given-names>S.</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Bonsignori</surname><given-names>Mattia</given-names></name><xref rid="aff12" ref-type="aff">12</xref><xref rid="aff13" ref-type="aff">13</xref></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>LaTonya D.</given-names></name><xref rid="aff12" ref-type="aff">12</xref></contrib><contrib contrib-type="author"><name><surname>Haynes</surname><given-names>Barton F.</given-names></name><xref rid="aff12" ref-type="aff">12</xref><xref rid="aff13" ref-type="aff">13</xref><xref rid="aff14" ref-type="aff">14</xref></contrib><contrib contrib-type="author"><name><surname>Doria-Rose</surname><given-names>Nicole</given-names></name><xref rid="aff15" ref-type="aff">15</xref></contrib><contrib contrib-type="author"><name><surname>Mascola</surname><given-names>John R.</given-names></name><xref rid="aff15" ref-type="aff">15</xref></contrib><contrib contrib-type="author"><name><surname>Montefiori</surname><given-names>David C.</given-names></name><xref rid="aff12" ref-type="aff">12</xref><xref rid="aff16" ref-type="aff">16</xref></contrib><contrib contrib-type="author"><name><surname>Barouch</surname><given-names>Dan H.</given-names></name><email>dbarouch@bidmc.harvard.edu</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff11" ref-type="aff">11</xref><xref rid="fn2" ref-type="fn">18</xref><xref rid="fn3" ref-type="fn">19</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author"><name><surname>Korber</surname><given-names>Bette</given-names></name><email>btk@lanl.gov</email><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="fn2" ref-type="fn">18</xref><xref rid="cor2" ref-type="corresp">&#x02217;&#x02217;</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA</aff><aff id="aff2"><label>2</label>Los Alamos National Laboratory, Los Alamos, NM 87545, USA</aff><aff id="aff3"><label>3</label>New Mexico Consortium, Los Alamos, NM 87545, USA</aff><aff id="aff4"><label>4</label>Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA</aff><aff id="aff5"><label>5</label>Massachusetts General Hospital, Boston, MA 02114, USA</aff><aff id="aff6"><label>6</label>Harvard Medical School, Boston, MA 02114, USA</aff><aff id="aff7"><label>7</label>Division of Molecular Medicine, Children&#x02019;s Hospital, Boston, MA 02115, USA</aff><aff id="aff8"><label>8</label>Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA</aff><aff id="aff9"><label>9</label>Departments of Chemistry and Biochemistry, University of Colorado, Colorado Springs, CO 80918, USA</aff><aff id="aff10"><label>10</label>Department of Medicine and CFAR, University of Alabama at Birmingham, Birmingham, AL 35294, USA</aff><aff id="aff11"><label>11</label>Ragon Institute of Massachusetts General Hospital, MIT, and Harvard, Boston, MA 02114, USA</aff><aff id="aff12"><label>12</label>Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA</aff><aff id="aff13"><label>13</label>Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA</aff><aff id="aff14"><label>14</label>Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA</aff><aff id="aff15"><label>15</label>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20814, USA</aff><aff id="aff16"><label>16</label>Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author <email>dbarouch@bidmc.harvard.edu</email></corresp><corresp id="cor2"><label>&#x02217;&#x02217;</label>Corresponding author <email>btk@lanl.gov</email></corresp><fn id="fn1"><label>17</label><p id="ntpara0010">These authors contributed equally</p></fn><fn id="fn2"><label>18</label><p id="ntpara0015">These authors contributed equally</p></fn><fn id="fn3"><label>19</label><p id="ntpara0020">Lead Contact</p></fn></author-notes><pub-date pub-type="pmc-release"><day>09</day><month>1</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.--><pub-date pub-type="ppub"><day>09</day><month>1</month><year>2019</year></pub-date><volume>25</volume><issue>1</issue><fpage>59</fpage><lpage>72.e8</lpage><history><date date-type="received"><day>14</day><month>4</month><year>2018</year></date><date date-type="rev-recd"><day>6</day><month>7</month><year>2018</year></date><date date-type="accepted"><day>14</day><month>11</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 The Author(s)</copyright-statement><copyright-year>2018</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><title>Summary</title><p>Eliciting HIV-1-specific broadly neutralizing antibodies (bNAbs) remains a challenge for vaccine development, and the potential of passively delivered bNAbs for prophylaxis and therapeutics is being explored. We used neutralization data from four large virus panels to comprehensively map viral signatures associated with bNAb sensitivity, including amino acids, hypervariable region characteristics, and clade effects across four different classes of bNAbs. The bNAb signatures defined for the variable loop 2 (V2) epitope region of HIV-1 Env were then employed to inform immunogen design in a proof-of-concept exploration of signature-based epitope targeted (SET) vaccines. V2 bNAb signature-guided mutations were introduced into Env 459C to create a trivalent vaccine, and immunization of guinea pigs with V2-SET vaccines resulted in increased breadth of NAb responses compared with Env 459C alone. These data demonstrate that bNAb signatures can be utilized to engineer HIV-1 Env vaccine immunogens capable of eliciting antibody responses with greater neutralization breadth.</p></abstract><abstract abstract-type="graphical" id="abs0015"><title>Graphical Abstract</title><fig id="undfig1" position="anchor"><graphic xlink:href="fx1"/></fig></abstract><abstract abstract-type="author-highlights" id="abs0020"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">HIV-1 bNAb sensitivity signatures from 4 large virus panels mapped across 4 Ab classes</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">Non-contact hypervariable region characteristics are critical for bNAb sensitivity</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">HIV-1 Env 459C used alone as a vaccine can elicit modest tier 2 NAbs in guinea pigs</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">V2 bNAb signature-guided modifications in 459C enhanced neutralization breadth</p></list-item></list></p></abstract><abstract abstract-type="teaser" id="abs0025"><p>HIV-1 Env amino acid signatures associated with sensitivity to broadly neutralizing antibodies were systematically defined from large neutralization panels. V2 signatures were incorporated in a trivalent vaccine to enhance epitope exposure and to include common epitope variants, resulting in increased neutralization breadth against heterologous viruses in a guinea pig model.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>HIV-1</kwd><kwd>broadly neutralizing antibodies</kwd><kwd>signature analysis</kwd><kwd>machine learning</kwd><kwd>vaccine design</kwd><kwd>V2-apex antibodies</kwd><kwd>hypervariable regions</kwd></kwd-group></article-meta><notes><p id="misc0010">Published: January 9, 2019</p></notes></front><body><sec id="sec1"><title>Introduction</title><p id="p0030">Vaccine induction of broadly neutralizing antibodies (bNAbs) against diverse global tier 2 HIV-1 strains remains an unsolved challenge for the HIV-1 vaccine field. There has been some progress in animal models (<xref rid="bib28" ref-type="bibr">Escolano et&#x000a0;al., 2016</xref>, <xref rid="bib75" ref-type="bibr">Saunders et&#x000a0;al., 2017</xref>), but human trials have yet to elicit bNAbs, although NAbs with varying levels of breadth arise during natural infection (<xref rid="bib42" ref-type="bibr">Hraber et&#x000a0;al., 2014b</xref>). bNAbs typically develop slowly during chronic infection as the virus diversifies under immune pressure and B cell lineages adapt to the evolving virus (<xref rid="bib6" ref-type="bibr">Bonsignori et&#x000a0;al., 2017b</xref>, <xref rid="bib27" ref-type="bibr">Doria-Rose et&#x000a0;al., 2014</xref>, <xref rid="bib54" ref-type="bibr">Liao et&#x000a0;al., 2013</xref>, <xref rid="bib89" ref-type="bibr">Wu et&#x000a0;al., 2015</xref>). bNAb breadth and potency are evaluated using large panels of HIV-1 Envelope (Env) pseudoviruses that sample global HIV-1 diversity (<xref rid="bib41" ref-type="bibr">Hraber et&#x000a0;al., 2014a</xref>) or the C clade diversity of Southern Africa (<xref rid="bib70" ref-type="bibr">Rademeyer et&#x000a0;al., 2016</xref>).</p><p id="p0035">We used data from 4 large neutralization panels for a more comprehensive mapping of viral signatures associated with bNAb sensitivity than undertaken previously (<xref rid="bib16" ref-type="bibr">Chuang et&#x000a0;al., 2013</xref>, <xref rid="bib29" ref-type="bibr">Evans et&#x000a0;al., 2014</xref>, <xref rid="bib31" ref-type="bibr">Ferguson et&#x000a0;al., 2013</xref>, <xref rid="bib86" ref-type="bibr">West et&#x000a0;al., 2013</xref>). Signature sites were identified using a strategy that incorporates a phylogenetic correction (<xref rid="bib37" ref-type="bibr">Gnanakaran et&#x000a0;al., 2010</xref>) for amino acids (AAs) and potential N-linked glycosylation sites (PNGSs) (<xref rid="bib19" ref-type="bibr">Crispin and Doores, 2015</xref>), and we also explored the impacts of hypervariable region characteristics and clades. Recurrent signature patterns were found among bNAbs with shared specificities (<xref rid="bib14" ref-type="bibr">Burton and Hangartner, 2016</xref>).</p><p id="p0040">We next used variable V2 apex (V2) epitope bNAb signatures to inform HIV-1 Env immunogen design in a proof-of-concept exploration of an approach we call signature-based epitope targeted (SET) vaccines. Other vaccine design strategies include engaging bNAb germline precursors (<xref rid="bib79" ref-type="bibr">Steichen et&#x000a0;al., 2016</xref>), using polyvalent sets to capture diversity (<xref rid="bib50" ref-type="bibr">Korber et&#x000a0;al., 2017</xref>), lineage-based designs (<xref rid="bib6" ref-type="bibr">Bonsignori et&#x000a0;al., 2017b</xref>), and engineered native-like Envs (e.g., SOSIPs) (<xref rid="bib72" ref-type="bibr">Sanders et&#x000a0;al., 2013</xref>, <xref rid="bib79" ref-type="bibr">Steichen et&#x000a0;al., 2016</xref>). SOSIP vaccines elicit robust autologous NAbs that have limited breadth in rabbits and non-human primates (NHPs) (<xref rid="bib66" ref-type="bibr">Pauthner et&#x000a0;al., 2017</xref>, <xref rid="bib73" ref-type="bibr">Sanders et&#x000a0;al., 2015</xref>).</p><p id="p0045">Our SET vaccine design started with the Env 459C (<xref rid="bib11" ref-type="bibr">Bricault et&#x000a0;al., 2015</xref>), as 459C alone elicited modest neutralization of some tier 2 heterologous strains in guinea pigs. V2-SET immunogens are a trivalent combination of 459C wild-type (WT) plus two additional proteins designed by modifying 459C to include V2 bNAb signatures intended to both enhance V2 epitope exposure and include relevant variation. V2-SET vaccines expressed as either gp140 SOSIP trimers or foldon trimers elicited increased NAb breadth compared to 459C alone in guinea pigs, suggesting the potential utility of bNAb signatures in vaccine design.</p></sec><sec id="sec2"><title>Results</title><sec id="sec2.1"><title>Neutralization Data</title><p id="p0050">Four datasets measuring the sensitivity of bNAbs against panels of HIV-1 Envs were analyzed. Three panels sampled global viral diversity (<xref rid="bib41" ref-type="bibr">Hraber et&#x000a0;al., 2014a</xref>), and the other sampled only C clade, which dominates in Southern Africa (<xref rid="bib70" ref-type="bibr">Rademeyer et&#x000a0;al., 2016</xref>). <xref rid="mmc1" ref-type="supplementary-material">Table S1</xref> summarizes bNAb dataset inclusion, relationships, and provenance. bNAbs are grouped by epitope class: V2, V3 glycan (V3), CD4 binding site (CD4bs), and membrane proximal external region (MPER) (<xref rid="bib15" ref-type="bibr">Burton and Mascola, 2015</xref>). V2 and V3 bNAbs often have great potency but limited breadth, CD4bs have expanded breadth, and MPER has high breadth but low potency (<xref rid="fig1" ref-type="fig">Figures 1</xref>, <xref rid="mmc1" ref-type="supplementary-material">S1</xref>, and <xref rid="mmc1" ref-type="supplementary-material">S2</xref>). Heatmaps displaying inhibitory concentrations of 50% (IC<sub>50</sub>) data illustrate shared pattern sensitivity across bNAb classes (<xref rid="fig1" ref-type="fig">Figures 1</xref> and <xref rid="mmc1" ref-type="supplementary-material">S1</xref>), enabling the definition of common bNAb class signatures.<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>Heatmaps Showing IC<sub>50</sub> Neutralization Titers for Dataset 4</p><p>Darker red hues indicate more potent neutralization and blue indicates undetected responses. Rows represent pseudoviruses, ordered differently in each panel to highlight commonalities in neutralization profiles across bNAbs in each class. The clade with the strongest clade effect is separated and indicated in green to the left. Key PNGSs are indicated by magenta. Among MPER bNAbs 2F5 is considered separately as it has a unique epitope.</p></caption><graphic xlink:href="gr1"/></fig></p></sec><sec id="sec2.2"><title>Neutralization Sensitivity and HIV-1 Clades</title><p id="p0055">bNAb sensitivity patterns are associated with HIV-1 clades, which have geographic associations (<xref rid="bib52" ref-type="bibr">Korber et&#x000a0;al., 2009</xref>). The V2 bNAb lineage CAP256.VRC26 is less potent against clade B viruses (<xref rid="bib25" ref-type="bibr">Doria-Rose et&#x000a0;al., 2016</xref>); diminished clade B potency extends across the V2 bNAb class (<xref rid="fig1" ref-type="fig">Figures 1</xref>, <xref rid="fig2" ref-type="fig">2</xref>A, and <xref rid="mmc1" ref-type="supplementary-material">S2</xref>). CD4bs bNAbs are more sensitive to clade A viruses, and some bNAbs are less sensitive to C clade, in particular 3BNC117 and VRC01 (<xref rid="fig1" ref-type="fig">Figures 1</xref>, <xref rid="fig2" ref-type="fig">2</xref>A, and <xref rid="mmc1" ref-type="supplementary-material">S2</xref>). MPER bNAbs are less potent against clade A. Circulating Recombinant Form 01 (CRF01) viruses, common in Southeast Asia, are extremely resistant to V3 bNAbs (<xref rid="fig1" ref-type="fig">Figures 1</xref> and <xref rid="mmc1" ref-type="supplementary-material">S2</xref>), which is driven by a PNGS shift from positions N332 to N334 found in 96% of CRF01 viruses (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref><underline>;</underline>
<xref rid="mmc1" ref-type="supplementary-material">Table S2</xref>). The N332 glycan directly contacts V3 bNAbs (<xref rid="bib49" ref-type="bibr">Kong et&#x000a0;al., 2013</xref>) and is essential for some, although PGT128 can tolerate its loss (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>). CRF01 was already highly diverse in central Africa when a founder seeded the Thai epidemic (<xref rid="bib51" ref-type="bibr">Korber et&#x000a0;al., 2000</xref>); African CRF01 viruses also lack the PNGS at N332. PNGS N332 frequencies vary between clades, correlating with overall clade sensitivity to V3 bNAbs (<xref rid="mmc1" ref-type="supplementary-material">Table S2</xref>); e.g., &#x0223c;40% of A clade viruses are resistant to most V3 bNAbs, and 43% lack the PNGS N332 (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>A; <xref rid="mmc1" ref-type="supplementary-material">Table S2</xref>). The N332 PNGS is under-represented among transmitted C clade viruses (<xref rid="bib70" ref-type="bibr">Rademeyer et&#x000a0;al., 2016</xref>), which may impact the efficacy of V3 bNAbs in southern Africa.<fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Env Characteristics Associated with bNAb Class Sensitivity</p><p>(A) Clade associations. Circles illustrate IC<sub>50</sub> titers from dataset 4, highlighting the 3 best represented clades: A in red, B in green, and C and CRF07 (which is clade C in Env) in blue. All others are gray. Boxplots show medians and quartiles. Patterns of relative clade sensitivity are consistent across bNAb classes. The p values are based on two-sided Wilcoxon tests comparing the most distinctive clade among A, B, and C to the other two clades. Points above the horizontal line were above the threshold of detection. The bolus of negative points in the &#x0201c;other&#x0201d; group for V3 bNAbs is primarily CRF01.</p><p>(B) Examples of hypervariable loop characteristic correlations with bNAb sensitivity, including one for each bNAb class (complete associations are in <xref rid="mmc2" ref-type="supplementary-material">Tables S3</xref>N&#x02013;S3Q). M-group and clade C data are from datasets 4 and 3, respectively. The p values are based on Kendall&#x02019;s tau.</p></caption><graphic xlink:href="gr2"/></fig></p></sec><sec id="sec2.3"><title>Amino Acid Signatures</title><p id="p0060">Signature patterns were identified by testing each AA and PNGS across Env alignments for associations with sensitivity to each bNAb in each of the 4 neutralization panels (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>), based on associations with either potency or detectable neutralization (<xref rid="mmc2" ref-type="supplementary-material">Tables S3</xref>A&#x02013;S3D; <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>). Key signature sites were initially identified using a method that corrects for phylogenetic artifacts (<xref rid="bib37" ref-type="bibr">Gnanakaran et&#x000a0;al., 2010</xref>) (<xref rid="mmc2" ref-type="supplementary-material">Tables S3</xref>E&#x02013;S3H). Once a site was deemed of interest by this stringent criterion, any significant associations within these key sites were listed (<xref rid="mmc2" ref-type="supplementary-material">Tables S3</xref>I&#x02013;S3L).<fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>Sequence LOGOs of AA Signatures by Antibody Class</p><p>This figure highlights the more robust signature sites in that they were supported by multiple lines of evidence&#x02014;they either had phylogenetically corrected associations supported by at least 2 datasets, were a signature site in a contact residue, or both. Not all bNAbs in a class are associated with every signature. Complete lists with detailed statistics are provided in <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>. Letter height represents AA frequencies in dataset 4. &#x0201c;O&#x0201d; represents an Asn in a PNGS motif. AAs associated with resistance and sensitivity are red and blue, respectively. AAs shown in green differ for different bNAbs within the class. (A) V3 bNAbs, (B) V2, (C) VH1-2 and VH1-46 CD4bs, and (D) MPER, with 10E8/4E10/DH511 on the left, 2F5 on the right, and red HXB2 position numbers highlighting opposing signatures between the two.</p></caption><graphic xlink:href="gr3"/></fig></p></sec><sec id="sec2.4"><title>CD4bs bNAbs</title><p id="p0065">While many CD4bs signatures are in contacts (<xref rid="fig3" ref-type="fig">Figures 3</xref> and <xref rid="mmc1" ref-type="supplementary-material">S3</xref>; <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>) and known to influence sensitivity (<xref rid="bib34" ref-type="bibr">Gao et&#x000a0;al., 2014</xref>, <xref rid="bib55" ref-type="bibr">Lynch et&#x000a0;al., 2015</xref>), most are outside of contact surfaces. We tested two CD4bs resistance signatures directly by introducing them into the CH505 transmitted-founder (TF) backbone. The G458Y signature mutation conferred complete resistance (IC<sub>50</sub> &#x0003e; 25&#x000a0;&#x003bc;g/mL) to VRC01 and 3BNC117, and both can neutralize the CH505 TF (IC<sub>50</sub> of 0.14 and 0.03&#x000a0;&#x003bc;g/mL, respectively). The non-contact T234N signature substitution introduced a PNGS at N234 that increased resistance to CD4bs bNAbs 5- to 7-fold, and IC<sub>50</sub> titers went from 0.36 to 1.82&#x000a0;&#x003bc;g/mL for CH235 and from 0.12 to 0.87&#x000a0;&#x003bc;g/mL for VRC01.</p></sec><sec id="sec2.5"><title>MPER bNAbs</title><p id="p0070">As their breadth is so great, most 10E8, 4E10, and DH511 signatures are associated with potency, except for rare mutations associated with complete resistance: W672L, F673L, and W680G (<xref rid="fig3" ref-type="fig">Figures 3</xref> and <xref rid="mmc1" ref-type="supplementary-material">S3</xref>; <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>). The 10E8-specific resistance signature N671T accounts for the increased breadth of DH511 lineage bNAbs over 10E8 (<xref rid="bib87" ref-type="bibr">Williams et&#x000a0;al., 2017</xref>). The MPER epitope signature K683R is also associated with resistance to CD4bs and V2 bNAbs (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>; <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>), consistent with MPER changes impacting overall neutralization sensitivity (<xref rid="bib8" ref-type="bibr">Bradley et&#x000a0;al., 2016</xref>). Clade C resistance to 2F5 may be explained by clade C not having an otherwise conserved Ala, A667 (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>).</p></sec><sec id="sec2.6"><title>V3 bNAbs</title><p id="p0075">Glycans that interact directly with V3 bNAbs (<xref rid="bib2" ref-type="bibr">Behrens et&#x000a0;al., 2016</xref>) and are positive signatures for neutralization are at positions N332, N301, and N295 (<xref rid="fig3" ref-type="fig">Figures 3</xref> and <xref rid="mmc1" ref-type="supplementary-material">S3</xref>; <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>). Similar to CD4bs and MPER bNAbs, V3 bNAb sensitivity signatures in the epitope were relatively conserved, with positive signatures as the most common variant (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>). In contrast, V3 bNAb signature sites between positions 336&#x02013;442 were extremely variable and so may contribute to more nuanced levels of potency. In the GDIR contact motif (<xref rid="bib77" ref-type="bibr">Sok et&#x000a0;al., 2016</xref>) only D325 is a signature, because the other 3 positions are nearly invariant.</p></sec><sec id="sec2.7"><title>V2 bNAbs</title><p id="p0080">V2 bNAbs contact glycans at positions N156 and N160. The PNGS N160 is critical for many V2 bNAbs, with a few exceptions that may be enabled by nearby glycans acting in compensatory role (<xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>; <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>) (<xref rid="bib56" ref-type="bibr">McLellan et&#x000a0;al., 2011</xref>). In contrast, 11 viruses of the 380 unique viruses in the combined datasets 3 and 4 lacked the PNGS at N156, and these 11 viruses had very similar distributions of IC<sub>50</sub> titers to viruses that had the PNGS site for all V2 bNAbs tested. PNGSs at positions N130 and N332 are associated with V2 bNAb resistance. The glycan at N130 is near the CAP256.VRC26 contact surface (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>) and it interacts with CH03 (<xref rid="bib38" ref-type="bibr">Gorman et&#x000a0;al., 2016</xref>), but glycans at N130 and N332 may also act indirectly through glycan dynamics (<xref rid="bib99" ref-type="bibr">Stewart-Jones et&#x000a0;al., 2016</xref>) or carbohydrate processing (<xref rid="bib2" ref-type="bibr">Behrens et&#x000a0;al., 2016</xref>). Many V2 bNAb contact signatures have been studied: K169 and K171 loss, and Q170K, confers resistance, while E/D164 increases CAP256.VRC26.25 sensitivity (<xref rid="bib26" ref-type="bibr">Doria-Rose et&#x000a0;al., 2012</xref>, <xref rid="bib25" ref-type="bibr">Doria-Rose et&#x000a0;al., 2016</xref>).</p></sec><sec id="sec2.8"><title>Evolutionary Counter-pressure</title><p id="p0085">Some resistance signatures come with a fitness cost (<xref rid="bib55" ref-type="bibr">Lynch&#x000a0;et&#x000a0;al., 2015</xref>). Also, some signatures are associated with resistance or sensitivity depending on the bNAb class (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>; <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>), including the PNGS at N130, associated with V2 bNAb resistance and CD4bs VRC03 sensitivity; the PNGS at N332, associated with V3 bNAb sensitivity and V2 bNAb resistance; and L165, associated with V2 bNAb sensitivity and V3 bNAb resistance (<xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>; <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>). Antibodies within a class can also have contradictory signatures. Some MPER signature AAs have opposing associations for 2F5 versus 4E10/10E8/DH511 (<xref rid="fig3" ref-type="fig">Figures 3</xref> and <xref rid="mmc1" ref-type="supplementary-material">S3</xref>; <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>). A negatively charged D279 is associated with VRC01 sensitivity and with 12A12 resistance, likely due to the local charge in the bNAb paratopes (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S3</xref>) (<xref rid="bib47" ref-type="bibr">Klein et&#x000a0;al., 2013</xref>). CD4bs signatures for&#x000a0;CDRH3 bNAbs (<xref rid="bib93" ref-type="bibr">Zhou et&#x000a0;al., 2015</xref>) often&#x000a0;had opposing signatures relative to VH1-2 or VH1-46 bNAbs (<xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>).</p></sec><sec id="sec2.9"><title>Clade Sensitivity</title><p id="p0090">Signature sites offer hypotheses to explain bNAb clade sensitivities. Four contact site candidates were proposed to contribute to the reduced reactivity of CAP256.VRC26 bNAbs with B clade viruses (<xref rid="bib25" ref-type="bibr">Doria-Rose et&#x000a0;al., 2016</xref>). We found an additional 17 signatures that may limit V2 bNAb potency against B clade viruses (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S4</xref>A). In contrast, CAP256.VRC26 bNAbs are most potent against clade C&#x000a0;viruses and 12 signatures may be relevant. CD4bs antibodies have enhanced potency against A clade viruses, and resistance signatures are relatively rare in A clade (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S4</xref>B); in contrast, 3BNC117 and VRC01 have reduced breadth and potency against C clade viruses (<xref rid="fig2" ref-type="fig">Figure 2</xref>).</p></sec><sec id="sec2.10"><title>Hypervariable Loops and Neutralization Sensitivity</title><p id="p0095">HIV-1 Env hypervariable regions evolve rapidly <italic>in&#x000a0;vivo</italic> by insertions and deletions, giving rise to extreme length variation and making alignments spanning these regions unreliable. These changes can mediate bNAb escape (<xref rid="bib7" ref-type="bibr">Bonsignori et&#x000a0;al., 2016</xref>, <xref rid="bib34" ref-type="bibr">Gao et&#x000a0;al., 2014</xref>, <xref rid="bib50" ref-type="bibr">Korber et&#x000a0;al., 2017</xref>). We use alignment-independent characteristics of these regions (length, net charge, and number of PNGSs) to identify patterns associated with bNAb resistance profiles. The strongest of these associations are included in <xref rid="mmc2" ref-type="supplementary-material">Tables S3</xref>M&#x02013;S3P, and examples are shown in <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B.</p><p id="p0100">Combined V1+V2 length was the strongest correlate with V3 bNAb neutralization resistance&#x02014;so insertions in either or both regions reduce sensitivity&#x02014;followed by the number of PNGSs in V1+V2 and V1 length (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B; <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>). V1 length variation played a critical role in the development of V3 bNAb DH270 lineage (<xref rid="bib5" ref-type="bibr">Bonsignori et&#x000a0;al., 2017a</xref>). A glycan in hypervariable V1 contacts PGT121-family bNAbs, enabling interactions when the key N332 glycan is absent. However, when N332 glycan is present, consistent with our signature predictions, removing this glycan enhances PGT121-family sensitivity (<xref rid="bib35" ref-type="bibr">Garces et&#x000a0;al., 2015</xref>).</p><p id="p0105">The strongest variable region correlation with V2 bNAb sensitivity was V2 loop net-positive charge (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B; <xref rid="mmc1" ref-type="supplementary-material">Table S6</xref>). The effect remained strong when only the V2 hypervariable region (positions 185&#x02013;190) was considered. V2 bNAbs have long anionic CDRH3 loops (<xref rid="bib26" ref-type="bibr">Doria-Rose et&#x000a0;al., 2012</xref>, <xref rid="bib56" ref-type="bibr">McLellan et&#x000a0;al., 2011</xref>), which may drive the preference for positive charge. Also, V1+V2 hypervariable region length was inversely correlated with V2 bNAb sensitivity (<xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>).</p><p id="p0110">Paradoxically, although CD4bs bNAbs can have great breadth, they bind near the V5 region which is subject to extreme length variation. Both V5 length and the number of PNGSs within V5 are associated with reduced CD4bs bNAb potency (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B; <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>). CD4bs bNAbs can be selected to tolerate changes in V5 length after they arise as escape mutations <italic>in&#x000a0;vivo</italic> (<xref rid="bib30" ref-type="bibr">Fera et&#x000a0;al., 2014</xref>). Long V1 and V2 regions also correlate with CD4bs bNAb resistance (<xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>) and mediate <italic>in&#x000a0;vivo</italic> escape (<xref rid="bib34" ref-type="bibr">Gao et&#x000a0;al., 2014</xref>). Hence, long V1 and V2 regions are associated with relative resistance to 3 major classes of bNAbs: CD4bs, V2,&#x000a0;and V3. At the population level, there are evolutionary counter-pressures against larger loops, as smaller hypervariable regions tend to be selected at transmission (<xref rid="bib23" ref-type="bibr">Derdeyn et&#x000a0;al., 2004</xref>). Unexpectedly, increasing numbers of PNGSs in V1 correlated with enhanced sensitivity to MPER bNAbs, particularly 10E8 (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B; <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>).</p></sec><sec id="sec2.11"><title>Machine Learning Predictions of Env Neutralization</title><p id="p0115">We next explored using bNAb signatures for sequence-based machine learning predictions of bNAb sensitivity. Using a Random Forest (RF) for IC<sub>50</sub> regression predictions, we compared prediction accuracies for 3 prefiltering strategies: (1) a standard prefilter, minimal-redundancy-maximal-relevance (mRMR) (<xref rid="bib69" ref-type="bibr">Peng et&#x000a0;al., 2005</xref>); (2) the full bNAb signatures for each antibody class, including AA, PNGS, clade, and variable loop characteristics; and (3) only signatures in contact sites. We evaluated predictions using leave-one-out cross validation for dataset 4, as well as for an independent C clade holdout set. The accuracy using the full signature was superior to mRMR (p&#x000a0;= 0.003, paired Wilcoxon, C clade holdout comparison), and to the contact-region-only signature (also p&#x000a0;= 0.003) (<xref rid="mmc1" ref-type="supplementary-material">Table S4</xref>); examples are shown in <xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>. We also tested positive/negative classification predictions using our prefilter strategies and RF, comparing them to a published method called IDEpi (<xref rid="bib40" ref-type="bibr">Hepler et&#x000a0;al., 2014</xref>); the methods were comparable (<xref rid="mmc1" ref-type="supplementary-material">Table S5</xref>). Hypervariable region characteristics were consistently among the most important factors for predicting IC<sub>50</sub> titers (<xref rid="mmc3" ref-type="supplementary-material">Table S6</xref>).<fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>Random Forest Signature-Based Prediction Accuracy</p><p>Leave-one-out cross-validation regression predictions using dataset 4 for one bNAb from each bNAb class. R<sup>2</sup> is the standard coefficient of determination; the p value is from Kendall&#x02019;s tau. The red line marks the threshold of detection. R<sup>2</sup> values remained significant when negative points were excluded: PG9,&#x000a0;R<sup>2</sup>&#x000a0;=&#x000a0;0.35, p&#x000a0;= 4&#x000a0;&#x000d7; 10<sup>&#x02212;14</sup>; 10&#x02013;1074, R<sup>2</sup>&#x000a0;= 0.27, p&#x000a0;= 2&#x000a0;&#x000d7; 10<sup>&#x02212;9</sup>; 3BNC117, R<sup>2</sup>&#x000a0;=&#x000a0;0.30, p&#x000a0;= 3&#x000a0;&#x000d7; 10<sup>&#x02212;9</sup>; and 10E8, R<sup>2</sup>&#x000a0;= 0.12, p&#x000a0;= 9&#x000a0;&#x000d7; 10<sup>&#x02212;7</sup>.</p></caption><graphic xlink:href="gr4"/></fig></p></sec><sec id="sec2.12"><title>V2-SET Vaccines</title><sec id="sec2.12.1"><title>Immunogen Design and Expression</title><p id="p0120">We next utilized V2 bNAb signatures to inform vaccine design, intending to increase V2 epitope exposure and represent relevant natural diversity within the epitope. V2-SET trivalent vaccines included 459C WT, which alone induced low-level neutralization of some tier 2 viruses plus two complementary immunogens, called Optimal (Opt) and Alternative (Alt) (<xref rid="fig5" ref-type="fig">Figures 5</xref>A and 5B; <xref rid="mmc1" ref-type="supplementary-material">Table S7</xref>). Opt introduced V2 bNAb virus sensitivity signatures into the 459C WT backbone, to enhance epitope expression, exposure, affinity, or relevant carbohydrate processing (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>A). Alt incorporated V2 bNAb sensitivity signatures outside of the contact region; however, within the epitope it captured natural diversity in V2 signature sites&#x02014;including globally common AAs complementary to those found in 459C WT and Opt&#x02014;even if associated with relative resistance (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>B). V2-SET immunogens also incorporated modified hypervariable regions with characteristics favoring V2 bNAb sensitivity, including short V1 and V2 hypervariable regions with a positively charged V2 region (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B; <xref rid="mmc2" ref-type="supplementary-material">Tables S3</xref>N&#x02013;S3R). The WT Env T250_4 met these criteria and was also highly&#x000a0;sensitive to <italic>both</italic> V2 and V3 bNAbs (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>). Hypothesizing T250_4 hypervariable regions might improve polyclonal responses to both bNAb classes, we used T250_4&#x02019;s V1 and V2 regions in our V2-SET constructs (<xref rid="mmc1" ref-type="supplementary-material">Table S7</xref>).<fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>V2-SET Vaccine Design and Production</p><p>(A and B) Structural mapping (PDB: <ext-link ext-link-type="uri" xlink:href="pdb:5FYJ" id="intref0180">5FYJ</ext-link>) of mutations introduced into 459C WT (<xref rid="mmc1" ref-type="supplementary-material">Table S7</xref>) to create (A) Opt and (B) Alt V2-SET vaccine constructs. Spheres are color-coded to indicate AA modifications associated with sensitivity or resistance. Opt constructs uniformly carry sensitivity signatures. Alt constructs carry mutations that enhance sensitivity outside the core epitope, but in the epitope introduce signature mutations complementary to 459C WT and Opt to capture epitope diversity.</p><p>(C) Gel filtration chromatography traces of gp140 V2-SET immunogens run on a Superose 6 column (foldon) or Superdex 200 column (SOSIP). Coomassie stained SDS-PAGE of purified Envs are next to each trace with molecular weight standards noted.</p><p>(D) Guinea pig vaccination regimens. Animals were vaccinated intramuscularly in the quadriceps with 100&#x000a0;&#x003bc;g total immunogen at weeks 0, 4, and 8; n is the group size.</p></caption><graphic xlink:href="gr5"/></fig></p><p id="p0125">The V2-SET gp140s were produced in 293T cells by transient transfection as either SOSIP or foldon immunogens. The gp140 foldon contains a C-terminal T4-fibritin trimerization domain following the MPER and is not cleaved by furin (<xref rid="bib33" ref-type="bibr">Frey et&#x000a0;al., 2008</xref>). The gp140 SOSIP is a native-like trimer truncated before the MPER and cleaved by furin (<xref rid="bib79" ref-type="bibr">Steichen et&#x000a0;al., 2016</xref>). Each purified Env protein ran as a single symmetrical peak by size exclusion chromatography, and as a single band on SDS-PAGE (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>C). We could not produce a stable V2 Alt SOSIP.</p><p id="p0130">The antigenic properties of the V2-SET foldon immunogens&#x000a0;were probed using surface plasmon resonance (<xref rid="mmc1" ref-type="supplementary-material">Tables S5</xref>A&#x02013;S5C). Soluble CD4 (<xref rid="bib53" ref-type="bibr">Kwong et&#x000a0;al., 1998</xref>) and V3 bNAb 10&#x02013;1074 both bound to all three. V2 bNAb PG16 bound Opt and Alt immunogens more robustly than 459C WT, consistent with increased V2 exposure. Trimer-specific V2 bNAbs PGT145 and PGDM1400 bound robustly to SOSIP but not to foldon gp140s, consistent with SOSIP gp140s being native-like (<xref rid="bib72" ref-type="bibr">Sanders et&#x000a0;al., 2013</xref>, <xref rid="bib79" ref-type="bibr">Steichen et&#x000a0;al., 2016</xref>).</p></sec><sec id="sec2.12.2"><title>Immunogenicity of V2-SET Env Vaccines</title><p id="p0135">Guinea pigs were immunized three times at monthly intervals (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>D), intramuscularly in the quadriceps, with a total of 100&#x000a0;&#x003bc;g Env (divided equally among immunogens in cocktails) formulated with CpG/Emulsigen adjuvant. Animals were bled 4&#x000a0;weeks after each vaccination, with peak immunogenicity at week 12. Binding responses were assessed by ELISA using the immunogens and a small panel of additional Envs expressed as gp140s, and V1/V2 gp70 scaffolds (<xref rid="bib46" ref-type="bibr">Kayman et&#x000a0;al., 1994</xref>) (<xref rid="mmc1" ref-type="supplementary-material">Figures S5</xref>D&#x02013;S5E). All vaccination regimens elicited comparable high magnitude binding responses with similar kinetics. Furthermore, all vaccines elicited tier-1 NAb responses against easy-to-neutralize viruses (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>F).</p><p id="p0140">Trivalent V2-SET vaccines augmented the magnitude and breadth of neutralization against 20 tier 2 pseudoviruses (the standard global panel of 12 [<xref rid="bib22" ref-type="bibr">deCamp et&#x000a0;al., 2014</xref><underline>]</underline>, plus 8 additional) compared with 459C WT alone, using either the gp140 SOSIP or gp140 foldon vaccine platforms (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>). Using the gp140 foldon platform, the V2-SET Mixture (the 3 vaccine components co-delivered) and V2-SET Prime/Boost (V2 Opt prime and V2 Alt+459C WT boost) both improved the magnitude of tier 2 NAbs responses compared to 459C WT alone (p&#x000a0;= 0.006 and p&#x000a0;= 0.008, respectively, using a non-parametric permutation test). A median of 85% of the heterologous tier 2 viruses were neutralized in the V2-SET groups, compared to 55% in the 459C WT alone group (p&#x000a0;= 0.004, two-sided Wilcoxon rank sum) (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>B). Using the SOSIP platform the V2-SET Mixture similarly improved neutralization potency compared to SOSIP 459C WT alone (p&#x000a0;= 0.008), and a median of 65% of the heterologous tier 2 viruses tested were neutralized in the V2-SET group, compared to 30% for the 459C WT group (p&#x000a0;= 0.008) (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>A). In contrast, the BG505 SOSIP gp140 induced a median of 5% the heterologous tier 2 viruses tested, although one animal had more breadth (<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref>C).<fig id="fig6"><label>Figure&#x000a0;6</label><caption><p>V2-SET Vaccines Improve the Breadth and the Magnitude of Tier 2 NAbs Compared to BG505 and 459C WT</p><p>(A&#x02013;D) Heatmaps of neutralizing responses comparing groups of guinea pigs vaccinated with 459C WT, V2-SET, and BG505 vaccines. Monovalent vaccines: (A) BG505 and 459C WT SOSIP and (B) 459C WT gp140 foldon. Trivalent vaccines: (C) V2-SET SOSIP and (D) gp140 foldon vaccines delivered as either a mixture or prime boost. Columns represent tier 2 pseudoviruses (see key), ordered by sensitivity. Rows represent guinea pigs, organized by vaccine group. The potency of ID<sub>50</sub> responses increases from yellow to dark red, below threshold responses are blue. To compare the breadth of response between different vaccine regimens, the median number of detectable responses is reported for each vaccination regimen to the right of the heatmaps, and detectible responses per animal were compared by a two-sided Wilcoxon test. BG505 and 459C WT SOSIP vaccines were comparable (p&#x000a0;= 0.13), and V2-SET SOSIP vaccine responses were broader than either BG505 (p&#x000a0;= 0.02) or 459C WT (p&#x000a0;= 0.01). Responses elicited by the V2-SET foldon vaccine were broader than responses elicited by the 459C WT foldon vaccine (p&#x000a0;= 0.006).</p><p>(E and F) Magnitudes of tier 2 NAb responses to SOSIP and foldon vaccine groups, respectively. Responses that were at least 10 above the background are considered positive and are shown; the dotted line at an ID<sub>50</sub> titer of 100 is added for visual emphasis. Colors represent the vaccine groups (see key). Horizontal black lines are the median response to each pseudovirus. Response magnitudes were compared with a nonparametric permutation test (<xref rid="sec4" ref-type="sec">STAR&#x000a0;Methods</xref>). For SOSIP vaccines, there was no statistical difference in potency between BG505 and 459C WT vaccine groups (p&#x000a0;= 0.06), but V2-SET responses were more potent than both BG505 (p&#x000a0;= 0.007) and 459C WT (p&#x000a0;= 0.008). For gp140 foldon delivery, V2-SET responses were more potent than 459C WT (p&#x000a0;= 0.002).</p></caption><graphic xlink:href="gr6"/></fig></p><p id="p0145">We next explored the generalizability these findings. First, tier 2 NAb responses with the V2-SET vaccine were similarly enhanced compared to 459C WT using a different adjuvant, MPLA (<xref rid="bib62" ref-type="bibr">Nkolola et&#x000a0;al., 2014b</xref>) (<xref rid="mmc1" ref-type="supplementary-material">Figures S6</xref>A and S6B). Second, while V2 Opt and Alt delivered alone were immunogenic, they did not enhance neutralization breadth like the trivalent combination (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S6</xref>C). Third, the tier 2 NAb responses were mediated by purified IgG (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S7</xref>D). Finally, other previously studied multivalent Env cocktails involving natural sequence immunogens, a trivalent clade C vaccine (<xref rid="bib11" ref-type="bibr">Bricault et&#x000a0;al., 2015</xref>) and a tetravalent multiclade vaccine (<xref rid="bib10" ref-type="bibr">Bricault et&#x000a0;al., 2018</xref>), did not significantly enhance tier 2 breadth over 459C WT (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S6</xref>C). Together, these data suggest that the improved NAb breadth induced with the trivalent V2-SET vaccine was generalizable, dependent on the SET bioinformatic design, and could not be achieved by simple mixtures of WT Env immunogens.</p><p id="p0150">We also assessed post-vaccination antibody responses for binding to linear peptides spanning Env (<xref rid="bib80" ref-type="bibr">Stephenson et&#x000a0;al., 2015</xref>). Despite similar overall ELISA titers (<xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S5</xref>), V2-SET vaccines binding responses to linear V3 peptides were markedly lower than 459C WT, suggesting they were redirected away from non-neutralizing linear V3 epitopes (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>A). To assess whether the improved V2-SET tier 2 NAb responses resulted from V2-specific conformational antibodies, we constructed pseudoviruses that resulted in the loss of the PNGS at position N160&#x02014;a critical sensitivity signature for V2 bNAbs. The N160-PNGS-loss mutation pseudoviruses showed increased neutralization sensitivity to 459C WT vaccine-elicited NAbs, suggesting that a region partly shielded by the N160 glycan was targeted, but they also abrogated the enhancement in NAb potency achieved with V2-SET vaccine compared to the 459C WT vaccine (<xref rid="fig7" ref-type="fig">Figure&#x000a0;7</xref>B), suggesting that the improved the performance of the V2-SET vaccine over 459C WT depended on the PNGS at N160.<fig id="fig7"><label>Figure&#x000a0;7</label><caption><p>Mapping of Antibody Responses Elicited by V2-SET Vaccine</p><p>(A) Magnitude and position of binding antibody responses from guinea pig sera to linear 15-mer peptides on peptide microarrays from each gp140 foldon vaccine group. Each dot represents an average MFI (mean fluorescence intensity) per peptide that is positive for antibody binding within each vaccination group, standard deviation shown. Env regions are delineated by vertical lines, the V3 loop highlighted in red. Statistical differences for binding responses to peptides with starting positions in V3 as compared to 459C WT are shown. The p values are based on a Wilcoxon one-sided test; NS means not significant.</p><p>(B) Neutralizing titers against select pseudoviruses with a N160-dependent enhancement of V2-SET responses over 459C WT. ID<sub>50</sub> titers in guinea pigs vaccinated with 459C WT and V2-SET vaccines against the native pseudoviruses are shown by dots, and against the N160 glycan deletion mutant (T162I) pseudoviruses by squares. Colors represent the particular gp140 foldon vaccination regimen: black is 459C WT, red is V2-SET mixture, and blue is V2-SET prime/boost. The top plots show ID<sub>50</sub> titers for each guinea pig. The dotted line at 20 marks the limit of detection. The bottom plots show the geometric means of the NAb titers from the top plot (over the animals vaccinated by the same vaccine and tested on the same pseudovirus as in the top plot), normalized to 459C WT. The p values from Wilcoxon pairwise comparisons are shown in red. NS, not significant.</p></caption><graphic xlink:href="gr7"/></fig></p></sec></sec></sec><sec id="sec3"><title>Discussion</title><p id="p0155">We defined HIV-1 Env bNAb signatures using neutralization data from four large virus panels to provide an unprecedented level of bNAb signature mapping&#x02014;including hundreds of AA and PNGS signatures, as well as critical hypervariable region characteristics&#x02014;for over 50 NAbs. The accuracy of Env sequence-based machine learning predictions of IC<sub>50</sub> titers were generally improved by focusing on relevant signatures and hypervariable region characteristics that were consistently highly ranked as key features for accurate predictions; thus supporting the consideration of these characteristics in vaccine design. Such machine-learning-based predictions of bNAb sensitivity levels across populations of Env sequences may ultimately be useful for modeling the relative sensitivity of a set of bNAbs across a regional epidemic targeted for treatment and for interpreting results of bNAb-based prevention and therapeutic clinical studies. Our data also highlight the importance of HIV-1 clades for both bNAb passive infusion studies and vaccine studies.</p><p id="p0160">We also developed a signature-based approach to Env immunogen design using the V2 bNAb signature patterns to inform the design of a trivalent V2-SET vaccine. Induction of heterologous tier 2 NAbs has proven to be a major challenge for the HIV-1 vaccine field, and to date, the breadth of tier 2 NAbs induced by vaccines has been modest in both small and large animal models. The native-like BG505 SOSIP trimer induces potent autologous NAbs but with minimal tier 2 NAb breadth (<xref rid="bib66" ref-type="bibr">Pauthner et&#x000a0;al., 2017</xref>, <xref rid="bib73" ref-type="bibr">Sanders et&#x000a0;al., 2015</xref>). The trivalent V2-SET vaccine induced greater breadth of tier 2 NAb responses than the 459C SOSIP trimer alone, and both proved superior to the BG505 SOSIP trimer. The improved NAb breadth using V2-SET antigens was reproducible in guinea pig vaccination studies and generalizable using two common HIV-1 Env trimer platforms (SOSIP and foldon gp140s) and two adjuvants (CpG/Emulsigen and MPLA). Moreover, the enhanced NAb breadth was not observed with two cocktails of natural sequence HIV-1 Env immunogens. Although the magnitude of the tier 2 NAb responses remained low to moderate, these data demonstrate the proof-of-concept that bNAb signatures can contribute to the design of next-generation HIV-1 Env immunogens.</p></sec><sec id="sec4"><title>STAR&#x02605;Methods</title><sec id="sec4.1"><title>Key Resources Table</title><p id="p0165"><table-wrap id="undtbl1" position="float"><table frame="hsides" rules="groups"><thead><tr><th>REAGENT or RESOURCE</th><th>SOURCE</th><th>IDENTIFIER</th></tr></thead><tbody><tr><td colspan="3"><bold>Antibodies</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>10-1074</td><td>Laboratory of Michel Nussenzweig, Rockefeller University</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_2491062" id="intref0010">AB_2491062</ext-link>; <xref rid="bib58" ref-type="bibr">Mouquet et&#x000a0;al. (2012)</xref></td></tr><tr><td>PG16</td><td>Polymun</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_2491031" id="interref0185">AB_2491031</ext-link>; Cat#AB016</td></tr><tr><td>PGT145</td><td>Catalent</td><td>RRID: <ext-link ext-link-type="uri" xlink:href="nif-antibody:AB_2491054" id="intref0015">AB_2491054</ext-link></td></tr><tr><td>PGDM1400</td><td>Catalent</td><td><xref rid="bib78" ref-type="bibr">Sok et&#x000a0;al. (2014)</xref></td></tr><tr><td>HRP-conjugated goat anti-guinea pig secondary antibody</td><td>Jackson ImmunoResearch Laboratories</td><td>Cat#106-035-003</td></tr><tr><td>Alexa Fluor 647-conjugated AffiniPure Goat Anti-Guinea Pig IgG (H+L)</td><td>Jackson ImmunoResearch Laboratories</td><td>Cat#706-605-148</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Bacterial and Virus Strains</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>X1632 T162I pseudovirus</td><td>Laboratory of Christina Ochsenbauer, University of Alabama Birmingham</td><td>N/A</td></tr><tr><td>T250-4 T162I pseudovirus</td><td>Laboratory of Christina Ochsenbauer, University of Alabama Birmingham</td><td>N/A</td></tr><tr><td>BJOX2000 T162I pseudovirus</td><td>Laboratory of Christina Ochsenbauer, University of Alabama Birmingham</td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Chemicals, Peptides, and Recombinant Proteins</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>HIV-1 gp70 V1/V2 (ConC)</td><td>Immune Technology Corp</td><td>Cat#IT-001-213p</td></tr><tr><td>HIV-1 gp70 V1/V2 (Case A2)</td><td>Immune Technology Corp</td><td>Cat#IT-001-214p</td></tr><tr><td>HIV-1 gp70 V1/V2 (CN54)</td><td>Immune Technology Corp</td><td>Cat#IT-001-211p</td></tr><tr><td>HIV-1 gp70 V1/V2 (A244)</td><td>Immune Technology Corp</td><td>Cat#IT-001-212p</td></tr><tr><td>HBS-EP</td><td>GE Healthcare</td><td>Cat#BR100188</td></tr><tr><td>Soluble CD4</td><td>Laboratory of Bing Chen, Children&#x02019;s Hospital Boston</td><td><xref rid="bib32" ref-type="bibr">Freeman et&#x000a0;al. (2010)</xref></td></tr><tr><td>Amine Coupling Kit</td><td>GE Healthcare</td><td>Cat#BR100050</td></tr><tr><td>Pierce Recombinant Protein A</td><td>ThermoScientific</td><td>Cat#21184</td></tr><tr><td>Emulsigen</td><td>MVP Adjuvants</td><td>N/A</td></tr><tr><td>Monophosphoryl Lipid A from S. minnesota R595</td><td>InvivoGen</td><td>Cat#vac-mpla</td></tr><tr><td>SuperBlock T20 (TBS) Blocking Buffer</td><td>Thermo Scientific</td><td>Cat#37536</td></tr><tr><td>High-Capacity Protein A Agarose</td><td>Thermo Scientific</td><td>Cat# 89948</td></tr><tr><td>459C WT gp140 foldon</td><td><xref rid="bib11" ref-type="bibr">Bricault et&#x000a0;al. (2015)</xref></td><td>N/A</td></tr><tr><td>459C V2 Opt gp140 foldon</td><td>This paper</td><td>N/A</td></tr><tr><td>459C V2 Alt gp140 foldon</td><td>This paper</td><td>N/A</td></tr><tr><td>459C WT SOSIP</td><td>This paper</td><td>N/A</td></tr><tr><td>459C V2 Opt SOSIP</td><td>This paper</td><td>N/A</td></tr><tr><td>C97ZA012 gp140 foldon</td><td><xref rid="bib63" ref-type="bibr">Nkolola et&#x000a0;al., (2010)</xref></td><td>N/A</td></tr><tr><td>405C gp140 foldon</td><td><xref rid="bib11" ref-type="bibr">Bricault et&#x000a0;al., (2015)</xref></td><td>N/A</td></tr><tr><td>92UG037 gp140 foldon</td><td><xref rid="bib63" ref-type="bibr">Nkolola et&#x000a0;al., (2010)</xref></td><td>N/A</td></tr><tr><td>PVO.4 gp140 foldon</td><td><xref rid="bib96" ref-type="bibr">Li et&#x000a0;al., (2005)</xref></td><td>Accession number: <ext-link ext-link-type="uri" xlink:href="ncbi-n:AY835444" id="intref0020">AY835444</ext-link></td></tr><tr><td>Mosaic gp140 foldon</td><td><xref rid="bib61" ref-type="bibr">Nkolola et&#x000a0;al., (2014a)</xref></td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Deposited Data</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Neutralizing antibody signatures will be deposited in the Los Alamos HIV database and accessible through the Genome Browser, the Neutralizing Antibody relational database, and the Env annotation tables.</td><td>Los Alamos HIV Database</td><td><ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/content/immunology/neutralizing_ab_resources.html" id="intref0025">https://www.hiv.lanl.gov/content/immunology/neutralizing_ab_resources.html</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.hiv.lanl.gov/components/sequence/HIV/featuredb/search/env_ab_search_pub.comp" id="intref0030">www.hiv.lanl.gov/components/sequence/HIV/featuredb/search/env_ab_search_pub.comp</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.hiv.lanl.gov/content/sequence/genome_browser/browser.html" id="intref0035">www.hiv.lanl.gov/content/sequence/genome_browser/browser.html</ext-link></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Experimental Models: Cell Lines</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Human: 293T</td><td>ATCC</td><td>ATCC CRL-3216</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Experimental Models: Organisms/Strains</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Hartley guinea pigs: Outbred</td><td>Elm Hill Labs</td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Oligonucleotides</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>CpG: 5&#x02019;-TCGTCGTTGTCGTTTTGTCGTT-3&#x02019;</td><td>Midland Reagent Company</td><td>N/A</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Recombinant DNA</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>GeneArt</td><td>Life Technologies</td><td>Cat#817003DE</td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Software and Algorithms</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>Softmax Pro-4.7.1</td><td>Molecular Devices</td><td><ext-link ext-link-type="uri" xlink:href="https://www.moleculardevices.com/systems/microplate-readers/softmax-pro-7-software" id="intref0040">https://www.moleculardevices.com/systems/microplate-readers/softmax-pro-7-software</ext-link></td></tr><tr><td>GenePix Pro 7 software</td><td>Molecular Devices</td><td><ext-link ext-link-type="uri" xlink:href="https://www.moleculardevices.com/en/asset/br/data-sheets/genepix-pro-software-datasheet-v7-rev-b" id="intref0045">https://www.moleculardevices.com/en/asset/br/data-sheets/genepix-pro-software-datasheet-v7-rev-b</ext-link></td></tr><tr><td>GenePix Array List</td><td><xref rid="bib80" ref-type="bibr">Stephenson et&#x000a0;al., (2015)</xref></td><td>N/A</td></tr><tr><td>GenSig, a signature analysis web interface</td><td>Los Alamos HIV Database</td><td><ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/content/sequence/GENETICSIGNATURES/gs.html" id="intref0050">https://www.hiv.lanl.gov/content/sequence/GENETICSIGNATURES/gs.html</ext-link></td></tr><tr><td>CATNAP, Neutralization data resource</td><td>Los Alamos HIV Database</td><td><ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/components/sequence/HIV/neutralization/" id="intref0055">https://www.hiv.lanl.gov/components/sequence/HIV/neutralization/</ext-link></td></tr><tr><td>Filtered Forests</td><td>Los Alamos HIV Database, github</td><td><ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/content/sequence/FLTFORESTS/fltforests.html" id="intref0060">https://www.hiv.lanl.gov/content/sequence/FLTFORESTS/fltforests.html</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://github.com/hivdb-lanl/FilteredForests" id="intref0065">https://github.com/hivdb-lanl/FilteredForests</ext-link></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td colspan="3"><bold>Other</bold></td></tr><tr><td colspan="3"><hr/></td></tr><tr><td>RepliTope Antigen Collection HIV Ultra slides</td><td>JPT Peptide Technologies GmbH</td><td>Cat#RT-HD_HIV</td></tr><tr><td>CM5 Chips</td><td>GE Healthcare</td><td>Cat#BR100012</td></tr></tbody></table></table-wrap></p></sec><sec id="sec4.2"><title>Contact for Reagent and Resource Sharing</title><p id="p0170">Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dan Barouch (<ext-link ext-link-type="uri" xlink:href="mailto:dbarouch@bidmc.harvard.edu" id="intref0070">dbarouch@bidmc.harvard.edu</ext-link>).</p></sec><sec id="sec4.3"><title>Experimental Model and Subject Details</title><sec id="sec4.3.1"><title>Human Subjects</title><p id="p0175">The HIV-1 bNAbs used in this study were all isolated in the context of other studies (<xref rid="mmc1" ref-type="supplementary-material">Table S1</xref>). The Env pseudoviruses are all part of widely used standard panels. Human specimens used to derive these reagents are de-identified and considered exempt by the Duke University IRB, and the exemption approved by the Los Alamos National Lab IRB.</p></sec><sec id="sec4.3.2"><title>Cell Lines</title><p id="p0180">Human endothelial kidney 293T cells (ATCC) were used for transient transfection of HIV-1 Env expressing plasmids and stably transfected human endothelial kidney 293T cells (Codex Biosolutions) were utilized for the production of HIV-1 Env gp140 and SOSIP immunogens.</p></sec><sec id="sec4.3.3"><title>Guinea Pig Vaccinations</title><p id="p0185">Healthy, outbred, research-na&#x000ef;ve, female Hartley guinea pigs (bred at and purchased from Elm Hill) at between 350 and 500 grams and about 1 to 2&#x000a0;months of age were used for vaccination studies and housed at the Animal Research Facility of Beth Israel Deaconess Medical Center under approved Institutional Animal Care and Use Committee (IACUC) protocols. Animals were co-housed 2 to 5 animals per cage, based on animal weight. All animals were na&#x000ef;ve at the initiation of the study. Guinea pigs (5-15/group) were immunized with Env gp140 immunogens intramuscularly in the quadriceps bilaterally at 4-week intervals (weeks 0, 4, 8) for a total of 3 injections. Vaccine formulations for each guinea pig consisted of a total of 100&#x003bc;g of immunogen per injection formulated in 15% Emulsigen (vol/vol) oil-in-water emulsion (MVP Laboratories) and 50&#x000a0;&#x003bc;g CpG (Midland Reagent Company) or 10&#x000a0;&#x003bc;g Monophosphoryl lipid A (MPLA) (InvivoGen) as adjuvants. We also tested the V2-SET immunogen sequences in the context of the gp140 MD39 SOSIP constructs (<xref rid="bib79" ref-type="bibr">Steichen et&#x000a0;al., 2016</xref>), using a lengthened schedule of vaccinations at weeks 0, 8, and 24. Serum samples were obtained from the vena cava of anesthetized animals four weeks after each immunization as well as prior to vaccination for week 0, na&#x000ef;ve sera.</p></sec></sec><sec id="sec4.4"><title>Method Details</title><sec id="sec4.4.1"><title>Experimental Methods for Vaccine Evaluation</title><sec id="sec4.4.1.1"><title>Plasmids, Cell Lines, Protein Production, and Antibodies</title><p id="p0190">Our baseline immunogen was the C clade Env 459C, initially selected because it elicited tier 1B NAb responses (<xref rid="bib11" ref-type="bibr">Bricault et&#x000a0;al., 2015</xref>), and subsequently found to induce low levels of select tier 2 NAbs upon evaluation of larger tier 2 pseudovirus panels. The codon-optimized synthetic genes of the V2-SET HIV-1 Env gp140 foldon (gp140) and gp140 MD39 SOSIP (SOSIP) immunogens were produced by GeneArt (Life Technologies). All gp140 constructs contained a consensus leader signal sequence peptide, as well as a C-terminal foldon trimerization tag followed by a His-tag as described previously (<xref rid="bib33" ref-type="bibr">Frey et&#x000a0;al., 2008</xref>, <xref rid="bib63" ref-type="bibr">Nkolola et&#x000a0;al., 2010</xref>). Large scale production of HIV-1 Env gp140 foldon and SOSIPs were produced as described previously (<xref rid="bib63" ref-type="bibr">Nkolola et&#x000a0;al., 2010</xref>, <xref rid="bib61" ref-type="bibr">Nkolola et&#x000a0;al., 2014a</xref>, <xref rid="bib79" ref-type="bibr">Steichen et&#x000a0;al., 2016</xref>). Of note, the gp140 SOSIP immunogens were cleaved by furin and the gp140 foldon immunogens were not. Soluble two-domain CD4 was produced as described previously (<xref rid="bib32" ref-type="bibr">Freeman et&#x000a0;al., 2010</xref>). 10-1074 was generously provided by Michel Nussenzweig (Rockefeller University, New York, NY). PG16 was purchased from Polymun Scientific, PGT145 and PGDM1400 from Catalent, gp70 V1/V2 HIV-1 envelope scaffolds including ConC, Case A2, CN54, and A244 V1/V2 from Immune Technology Corp.</p></sec><sec id="sec4.4.1.2"><title>Surface Plasmon Resonance Binding Analysis</title><p id="p0195">SPR experiments were conducted on a Biacore 3000 (GE Healthcare) at 25&#x000b0;C utilizing HBS-EP [10&#x000a0;mM Hepes (pH 7.4), 150&#x000a0;mM NaCl, 3&#x000a0;mM EDTA, 0.005% P20] (GE Healthcare) as the running buffer. Immobilization of CD4 (&#x0223c;1,000 response units (RU)) or protein A (ThermoScientific) to CM5 chips was performed following the standard amine coupling procedure as recommended by the manufacturer (GE Healthcare). Select protein-protein interactions were analyzed using single-cycle kinetics consisting of four cycles of a 1-min association phase and a 4-min dissociation phase without regeneration between injections, followed by an additional cycle of a 1-min association phase and a 15-min dissociation phase, at a flow rate of 50&#x000a0;&#x003bc;L/min. Immobilized IgGs were captured at about 500 RU for 10-1074 and about 3,000 RU for PG16. Soluble gp140 foldon was then passed over the surface at increasing concentrations from 62.5&#x000a0;nM-1,000&#x000a0;nM. Regeneration was conducted with 35&#x000a0;mM NaOH, 1.3&#x000a0;M NaCl (pH 12) at 100&#x000a0;&#x003bc;L/min followed by 5-min equilibration in the HBS-EP buffer. For experiments run with PGDM1400 and PGT145 IgG, immobilized PGDM1400 and PGT145 IgGs were captured at between 150-200 RU. Binding experiments were conducted with a flow rate of 50&#x000a0;&#x003bc;l/min with a 2-minute associate phase and a 5-minute dissociation phase. Soluble gp140 foldon or gp140 SOSIP were then passed over the surface at increasing concentrations from 31.25&#x000a0;nM-500&#x000a0;nM. Regeneration was conducted with one injection (3 seconds) of 35&#x000a0;mM sodium hydroxide, 1.3&#x000a0;M sodium chloride at 100ul/min followed by a 3-minute equilibration phase in HBS-EP. Identical injections over blank surfaces were subtracted from the binding data for analysis. All samples were run in duplicate and yielded similar kinetic results. Single curves of the duplicates are shown in all figures.</p></sec><sec id="sec4.4.1.3"><title>Endpoint ELISAs</title><p id="p0200">Serum binding antibodies against gp140 foldon and V1/V2 scaffolds were measured by endpoint enzyme-linked immunosorbant assays (ELISAs) as described previously (<xref rid="bib63" ref-type="bibr">Nkolola et&#x000a0;al., 2010</xref>). Briefly, ELISA plates (Thermo Scientific) were coated with individual gp140s or V1/V2 scaffolds (Immune Technology) and incubated overnight. Guinea pig sera were then added in serial dilutions and later detected with an HRP-conjugated goat anti-guinea pig secondary antibody (Jackson ImmunoResearch Laboratories). Plates were developed and read using the Spectramax Plus ELISA plate reader (Molecular Devices) and Softmax Pro-4.7.1 software. End-point titers were considered positive at the highest dilution that maintained an absorbance &#x0003e;2-fold above background values.</p></sec><sec id="sec4.4.1.4"><title>Peptide Microarrays</title><p id="p0205">RepliTope Antigen Collection HIV Ultra slides (JPT Peptide Technologies GmbH) arrays were generated, conducted, and analyzed using methods as described previously (<xref rid="bib80" ref-type="bibr">Stephenson et&#x000a0;al., 2015</xref>). These slides contain linear 15-mer peptides designed utilizing the HIV-1 global sequence database to provide coverage of HIV-1 global sequences (<xref rid="bib80" ref-type="bibr">Stephenson et&#x000a0;al., 2015</xref>). Briefly, microarray slides were incubated with guinea pig sera diluted 1/200 in SuperBlock T20 (TBS) Blocking Buffer (Thermo Scientific). Binding antibody responses were detected with Alexa Fluor 647-conjugated AffiniPure Goat Anti-Guinea Pig IgG (H+L) (Jackson ImmunoResearch Laboratories). All batches of slides were run in parallel with a control slide incubated with the secondary antibody only for background subtraction. Slides were scanned with a GenePix 4300A scanner (Molecular Devices) and analyzed with GenePix Pro 7 software and GenePix Array List (<xref rid="bib80" ref-type="bibr">Stephenson et&#x000a0;al., 2015</xref>). The threshold values for positivity were calculated as the point at which the chance that signal is noise as low as possible (P&#x0003c;10<sup>-16</sup>). The peak positive antibody binding responses to linear V3 Env peptides were further analyzed comparing the 459C WT and the V2-SET vaccines. Peptides with the highest magnitude binding responses were analyzed comparing geometric means over animals separately against each 15-mer peptide start position. Geometric means were calculated for each vaccination group resulting in a single point per vaccine per peptide sequence.</p></sec><sec id="sec4.4.1.5"><title>TZM.bl Neutralization Assay for Vaccine Sera</title><p id="p0210">All IC<sub>50</sub> data for the large neutralization panels were obtained using the validated luciferase-based TZM.bl assay (<xref rid="bib74" ref-type="bibr">Sarzotti-Kelsoe et&#x000a0;al., 2014</xref>); most antibodies to a maximum concentration of 50&#x000a0;&#x003bc;g/ml. For vaccine responses, 20 tier 2 pseudoviruses were used in the TZM.bl neutralization assay: the standardized global panel of 1HIV-1 reference strains independently selected to be representative of larger global panels (<xref rid="bib22" ref-type="bibr">deCamp et&#x000a0;al., 2014</xref>) and a panel of 8 additional tier 2 pseudoviruses selected because they were relatively sensitive to human sera (falling in the top quartile of geometric mean serological reactivity of the tier 2 panel), were sensitive to the V2 bNAb monoclonals (<xref rid="bib91" ref-type="bibr">Yoon et&#x000a0;al., 2015</xref>), and were relatively close in sequence to the V2-SET vaccines in the neutralization signature positions. The 8 additional pseudoviruses were added as an <italic>a priori</italic> attempt to increase the chances of getting a positive signal, but when tested were found to be very comparable in sensitivity to the global panel. The rationally selected tier 2 pseudoviruses included clade C (Du156.12, CT349_39_16, 234_F1_15_57, CNE58, and CA240_A5.5), CRF 02_AG (T250_4), CRF 07_BC (CNE20), and CRF 01_AE (C3347_C11) strains. For purification of guinea pig polyclonal IgG from sera, High-Capacity Protein A Agarose (Thermo Scientific) was utilized following manufacturer&#x02019;s instructions. After purification by protein A, polyclonal IgG samples were buffer exchanged into 1X phosphate buffered saline, pH 7.4 (Gibco) utilizing a EMD Millipore Amicon Ultra-15 Centrifugal Filter Unit (Millipore) at 4&#x000b0;C. Mutant pseudoviruses were generated with point mutations in V2/glycans to map NAb responses targeting these epitopes. Point mutations aiming to abrogate V2 antibody neutralization were selected to minimize disruptions in the virus backbone by representing mutations that occur commonly in nature. A T162I mutation was introduced into X1632, T250-4, and BJOX2000 to knock out the glycan at position N160; this mutations is relatively common among natural isolates.</p></sec></sec><sec id="sec4.4.2"><title>Sequence and Signature Analysis</title><sec id="sec4.4.2.1"><title>Signature analysis</title><p id="p0215">To systematically identify sites of interest, we used our phylogenetically corrected approach (<xref rid="bib37" ref-type="bibr">Gnanakaran et&#x000a0;al., 2010</xref>) to minimize false positives due to lineage effects (<xref rid="bib3" ref-type="bibr">Bhattacharya et&#x000a0;al., 2007</xref>), and q-values to constrain false positives due to multiple testing (<xref rid="bib81" ref-type="bibr">Storey and Tibshirani, 2003</xref>). These sites are summarized by antibody in <xref rid="mmc2" ref-type="supplementary-material">Tables S3</xref>A&#x02013;S3D, and population frequencies of signatures are displayed as LOGOs in <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>. Statistical details for all phylogenetically corrected signatures that met the statistical cutoff (q <underline>&#x0003c;</underline> 0.2) are provided in a summary table organized by antibody (<xref rid="mmc2" ref-type="supplementary-material">Tables S3</xref>E&#x02013;S3H). To be more inclusive, within each bNAb class, for sites that have either have a phylogenetically corrected signature for any bNAb within that class or are in the epitope binding region for a crystalized representative of the class, we also list in <xref rid="mmc2" ref-type="supplementary-material">Tables S3</xref>I&#x02013;S3L all AA and PNGS associations with a q-value &#x0003c;0.2, without the constraint of a phylogenetic correction, organized by Env position (<xref rid="mmc2" ref-type="supplementary-material">Tables S3</xref>I&#x02013;S3L). For comparison, published bNAb signatures from previous studies (<xref rid="bib17" ref-type="bibr">Chuang et&#x000a0;al., 2014</xref>, <xref rid="bib31" ref-type="bibr">Ferguson et&#x000a0;al., 2013</xref>, <xref rid="bib86" ref-type="bibr">West et&#x000a0;al., 2013</xref>) are also included in <xref rid="mmc2" ref-type="supplementary-material">Tables S3</xref>E&#x02013;S3L). This comparison shows that our analysis provides more detailed mapping of sites that may be relevant to the overall bNAb sensitivity than has been previously assembled. Because the bNAb field is advancing rapidly and new data are continuously accruing, we have also integrated our signature code into the CATNAP bioinformatics tool into the Los Alamos HIV Immunology Database (<xref rid="bib91" ref-type="bibr">Yoon et&#x000a0;al., 2015</xref>), allowing signature analysis to be conducted on-the-fly as new bNAb data is entered into the database.</p><p id="p0220">Phylogenetically corrected signature methods were described in detail in earlier publications (<xref rid="bib3" ref-type="bibr">Bhattacharya et&#x000a0;al., 2007</xref>, <xref rid="bib37" ref-type="bibr">Gnanakaran et&#x000a0;al., 2010</xref>). Briefly, for a simple uncorrected test, a 2 x 2 contingency table is generated where the data is divided about a phenotypic cutoff (<italic>e.g.</italic> &#x0201c;high&#x0201d; or &#x0201c;low&#x0201d; IC<sub>50</sub> values split about the median) and whether or not a sequence has a given amino acid at a given position, and a Fisher&#x02019;s exact test is used to assess statistical significance of each such contingency table. All amino acids are tested in all positions, and a false discovery rate (FDR) adjusted q-value (<xref rid="bib81" ref-type="bibr">Storey and Tibshirani, 2003</xref>) with a threshold of &#x0003c;0.2 used to define sites of interest, to be inclusive but still limit false negatives. This simple test can also be used to test associations with PNGS.</p><p id="p0225">Even with FDR, without a phylogenetic correction simple signatures can yield an extreme over-abundance of apparent results, and many associations will not be causative, but can be carried along by genetic linkage to a site where the variation has direct consequences. An example illustrating how can happen is provided in <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S7</xref>. In this example, the CRF01 clade is highly resistant to V3 bNAbs, and this is likely to be primarily driven the loss of the critical PNGS at N332 throughout the entire clade. But given the lack of reactivity for V3 bNAbs among CRF01 sequences, any amino acid highly enriched among CRF01 sequences will be associated with V3 bNAb resistance, yet most are likely to not be causative. An association that is still statistically supported after a phylogenetic correction, which requires that the correlation between the amino acid and the phenotype recur in sequences in dispersed locations throughout the tree, is more likely to reveal direct causative associations with the phenotype.</p><p id="p0230">For a phylogenetically corrected test, a maximum likelihood tree inferred by the signature code is used to estimate the most likely ancestral amino acids at branch points in the interior of the tree (<xref rid="bib3" ref-type="bibr">Bhattacharya et&#x000a0;al., 2007</xref>). For the branch point preceding each leaf node, the most likely amino acid is determined based on the most likely nucleotides at each position in the codon, which is translated to obtain the ancestral AA state of that leaf. A Fisher&#x02019;s exact test contingency table is based on whether the amino acid changed away from or stayed the same as the ancestral state, and whether the neutralizing phenotype is resistant or sensitive. Full statistics and contingency tables are provided in <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>, including detailed examples about how the contingency tables are constructed and their interpretation. As above, this phylogenetically corrected association test can also be used to analyze PNGS associations.</p><p id="p0235">Several cutoffs were used to define relative sensitivity and resistance: IC<sub>50</sub> titers being above (negative) or below (positive) the threshold of detection based on the highest concentration of Ab used, or partitioning the data about the median or the quartile responses. For a given amino acid at a given site, the results for phylogenetically corrected test with the lowest p-values are shown in <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref> E-H, with the test performed indicated in the table. If there are ties, they are broken by presenting the undetected vs detected responses (called PosNeg) when they are available, or by presenting the median over the quartile breakdowns if the tie is just between those two cutoffs. We also present uncorrected associations for all amino acids in <italic>positions of interest</italic> with bNAb sensitivity, again with a q-value cutoff of 0.2 (<xref rid="mmc2" ref-type="supplementary-material">Tables S3</xref>I&#x02013;S3L). This enabled us to explore the potential of amino acids at these interesting positions to contribute to levels of bNAb sensitivity, with a less stringent test than required surviving a phylogenetic correction. Sites were <italic>deemed of interest</italic> for this extended exploration by being either located within epitope, or by being found to be significantly associated with IC<sub>50</sub> titers using a phylogenetically corrected test for at least one bNAb in a class.</p><p id="p0240">Throughout this study, signatures were generally defined using the Fisher&#x02019;s exact test method described above, but we also explored using a non-parametric Wilcoxon rank sum test. In this case, the distributions of IC<sub>50</sub> titers were compared when an amino acid or PNGS site was present or absent in a given position, in a phylogenetically corrected analysis. The Wilcoxon test was generally less sensitive than a Fisher&#x02019;s test, however some CD4bs signatures were best defined using this test, and these results are provided in <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>M.</p></sec><sec id="sec4.4.2.2"><title>Antibody references</title><p id="p0245">Links between particular antibodies, references, and antibody provenance and relationships are provided in table format <xref rid="mmc1" ref-type="supplementary-material">Table S1</xref>. Fourteen V3 glycan bNAbs were studied (<xref rid="bib7" ref-type="bibr">Bonsignori et&#x000a0;al., 2016</xref>, <xref rid="bib35" ref-type="bibr">Garces et&#x000a0;al., 2015</xref>, <xref rid="bib45" ref-type="bibr">Julien et&#x000a0;al., 2013</xref>, <xref rid="bib49" ref-type="bibr">Kong et&#x000a0;al., 2013</xref>, <xref rid="bib58" ref-type="bibr">Mouquet et&#x000a0;al., 2012</xref>, <xref rid="bib68" ref-type="bibr">Pejchal et&#x000a0;al., 2011</xref>, <xref rid="bib82" ref-type="bibr">Trkola et&#x000a0;al., 1996</xref>, <xref rid="bib84" ref-type="bibr">Walker et&#x000a0;al., 2011</xref>). Ten V2 bNAbs were analyzed (<xref rid="bib4" ref-type="bibr">Bonsignori et&#x000a0;al., 2011</xref>, <xref rid="bib27" ref-type="bibr">Doria-Rose et&#x000a0;al., 2014</xref>, <xref rid="bib25" ref-type="bibr">Doria-Rose et&#x000a0;al., 2016</xref>, <xref rid="bib56" ref-type="bibr">McLellan et&#x000a0;al., 2011</xref>, <xref rid="bib78" ref-type="bibr">Sok et&#x000a0;al., 2014</xref>, <xref rid="bib85" ref-type="bibr">Walker et&#x000a0;al., 2009</xref>, <xref rid="bib84" ref-type="bibr">Walker et&#x000a0;al., 2011</xref>). Twenty-six CD4bs bNAbs were studied (<xref rid="bib5" ref-type="bibr">Bonsignori et&#x000a0;al., 2017a</xref>, <xref rid="bib13" ref-type="bibr">Burton et&#x000a0;al., 1991</xref>, <xref rid="bib18" ref-type="bibr">Corti et&#x000a0;al., 2010</xref>, <xref rid="bib24" ref-type="bibr">Diskin et&#x000a0;al., 2011</xref>, <xref rid="bib34" ref-type="bibr">Gao et&#x000a0;al., 2014</xref>, <xref rid="bib43" ref-type="bibr">Huang et&#x000a0;al., 2016</xref>, <xref rid="bib48" ref-type="bibr">Klein et&#x000a0;al., 2012</xref>, <xref rid="bib71" ref-type="bibr">Rudicell et&#x000a0;al., 2014</xref>, <xref rid="bib76" ref-type="bibr">Scheid et&#x000a0;al., 2011</xref>, <xref rid="bib83" ref-type="bibr">Wagh et&#x000a0;al., 2016</xref>, <xref rid="bib88" ref-type="bibr">Wu et&#x000a0;al., 2010</xref>, <xref rid="bib90" ref-type="bibr">Wu et&#x000a0;al., 2011</xref>, <xref rid="bib89" ref-type="bibr">Wu et&#x000a0;al., 2015</xref>, <xref rid="bib94" ref-type="bibr">Zhou et&#x000a0;al., 2013</xref>, <xref rid="bib93" ref-type="bibr">Zhou et&#x000a0;al., 2015</xref>). These were grouped into 3 types (<xref rid="bib93" ref-type="bibr">Zhou et&#x000a0;al., 2015</xref>): VH1-2 restricted, VH1-46 restricted, and those with a CDR H3 dominant mode of binding (<xref rid="mmc1" ref-type="supplementary-material">Table S1</xref>). The 4 MPER bNAbs studied were grouped by epitope, 2F5 or 4E10/10E8/DH511 (<xref rid="bib12" ref-type="bibr">Buchacher et&#x000a0;al., 1994</xref>, <xref rid="bib44" ref-type="bibr">Huang et&#x000a0;al., 2012</xref>, <xref rid="bib59" ref-type="bibr">Nelson et&#x000a0;al., 2007</xref>, <xref rid="bib87" ref-type="bibr">Williams et&#x000a0;al., 2017</xref>)</p></sec><sec id="sec4.4.2.3"><title>Phylogenetic trees</title><p id="p0250">Maximum likelihood trees were generated based on amino acid sequences using PhyML (<xref rid="bib39" ref-type="bibr">Guindon et&#x000a0;al., 2010</xref>) using the HIVb model (<xref rid="bib60" ref-type="bibr">Nickle et&#x000a0;al., 2007</xref>) (<ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/content/sequence/PHYML/interface.html" id="intref0075">https://www.hiv.lanl.gov/content/sequence/PHYML/interface.html</ext-link>), and represented using Rainbow Tree at the Los Alamos database (<ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/content/sequence/RAINBOWTREE/rainbowtree.html" id="intref0080">https://www.hiv.lanl.gov/content/sequence/RAINBOWTREE/rainbowtree.html</ext-link>), (<xref rid="bib64" ref-type="bibr">Paradis et&#x000a0;al., 2004</xref>).</p></sec><sec id="sec4.4.2.4"><title>Alignments</title><p id="p0255">The signature analysis tool requires as input codon-aligned nucleotide alignments, which we generated using the Gene Cutter tool&#x000a0;at&#x000a0;<ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/content/sequence/GENE_CUTTER/cutter.html" id="intref0085">https://www.hiv.lanl.gov/content/sequence/GENE_CUTTER/cutter.html</ext-link>, followed with hand editing. The complete dataset&#x000a0;alignments for data sets 3 and 4 and TZM.bl neutralization assay IC<sub>50</sub> data used in this study will be in the Special Interest Alignments page of the Los Alamos upon publication (<ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/content/sequence/HIV/SI_alignments/datasets.html" id="intref0090">https://www.hiv.lanl.gov/content/sequence/HIV/SI_alignments/datasets.html</ext-link>), and all of the neutralization data is publicly available through web-based <italic>CATNAP</italic> tool.</p></sec><sec id="sec4.4.2.5"><title>Sequence Representation</title><p id="p0260">Amino acids single-letter codes are used throughout. Standard HXB2 numbers is used throughout. The Los Alamos database Analyze Align tool (<ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/content/sequence/ANALYZEALIGN/analyze_align.html" id="intref0095">https://www.hiv.lanl.gov/content/sequence/ANALYZEALIGN/analyze_align.html</ext-link>) was used to generate sequence LOGOS (<xref rid="bib20" ref-type="bibr">Crooks et&#x000a0;al., 2004</xref>). LOGOS represent the frequency of amino acids in the illustrations included here, the measure of interest for this study, in the M group dataset 4, or in the C clade dataset 3. During the course of this study we have built convenient features into the Analyze Align LOGO generation tool: (1) when an N is embedded in a glycosylation site motif Nx[ST], we replace N with the letter O in the LOGO figure, otherwise we leave it as an N, (2) a grey box is used to indicate gaps inserted to maintain the alignment, (3) specific color schemes (e.g. our red/blue sensitivity/resistance color scheme) are now available, and (4) the tool can now make LOGOs of discontinuous sites by utilizing HXB2 numbering.</p></sec><sec id="sec4.4.2.6"><title>Hypervariable region characterization</title><p id="p0265">Hypervariable regions were characterized using the Los Alamos database <italic>Variable Region Characteristics</italic> tool: <ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/content/sequence/VAR_REG_CHAR/index.html" id="intref0100">https://www.hiv.lanl.gov/content/sequence/VAR_REG_CHAR/index.html</ext-link>. The variable loops V1, V2, V4, V5 each have hypervariable regions that frequently mutate by insertion and deletion. V3 loops have low levels of mutation by insertion and deletion, thus this region is readily aligned and was not considered hypervariable. The boundaries of these regions are shown in <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref> R. We systematically tested for correlations with each variable region characteristic (length, net charge, and number of PNGS) and Ab sensitivity for every Ab in each dataset, and calculated q-values to address multiple tests. If an Ab in a class had a q value of&#x000a0;&#x0003c; 0.20 with a V-loop correlate, it was considered of interest, and all other Abs of that same class were tracked and included in <xref rid="mmc2" ref-type="supplementary-material">Tables S3</xref>N&#x02013;S3Q. The hypervariable nature of these regions leads to rapid changes in them within the course of a given infection, so one would expect markedly diminished phylogenetic correlation with these hypervariable loop characteristics across a population, and thus a phylogenetic correction is not appropriate for these analyses. For each bNAb, we tested for correlations between all variable region characteristics and bNAb sensitivity, both including and excluding censored data (<xref rid="mmc2" ref-type="supplementary-material">Tables S3</xref>N&#x02013;S3Q).</p></sec></sec></sec><sec id="sec4.5"><title>Quantification and Statistical Analysis</title><sec id="sec4.5.1"><title>Sequence Analyses</title><sec id="sec4.5.1.1"><title>Signature Statistics</title><p id="p0270">To address multiple tests false discovery rate q-values were calculated (<xref rid="bib81" ref-type="bibr">Storey and Tibshirani, 2003</xref>). For all signature comparisons in <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>, a q-value <underline>&#x0003c;</underline> 0.2 was required for inclusion. We built our own Fisher&#x02019;s exact text code and q-value estimates into the signature analysis package (<xref rid="bib3" ref-type="bibr">Bhattacharya et&#x000a0;al., 2007</xref>). We use R (<ext-link ext-link-type="uri" xlink:href="http://www.r-project.org" id="intref0105">www.r-project.org</ext-link>/) to perform Wilcoxon rank sum comparisons of distributions, to perform Kendall&#x02019;s tau (<xref rid="bib57" ref-type="bibr">McLeod, 2011</xref>) to test for correlations, and to calculate q-values for addressing multiple tests when evaluating variable loop characteristics (<xref rid="bib21" ref-type="bibr">Dabney and Storey, 2013</xref>). Heatmaps were generated using the Los Alamos HIV database tool (<ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/content/sequence/HEATMAP/heatmap.html" id="intref0110">https://www.hiv.lanl.gov/content/sequence/HEATMAP/heatmap.html</ext-link>).</p></sec><sec id="sec4.5.1.2"><title>Machine learning predictions</title><p id="p0275">We used the Python package scikit-learn for machine learning predictions of bNAb sensitivity (<xref rid="bib67" ref-type="bibr">Pedregosa et&#x000a0;al., 2011</xref>). We initially compared several machine learning strategies (Random Forest, Support Vector Machine, and Linear Discriminant Analysis) using the M group cross-validation scores; the C clade holdout group was not considered during this selection process. Random Forest (RF) (<xref rid="bib9" ref-type="bibr">Breiman, 2001</xref>) strategies performed best, in particular the ExtraTreesRegressor and ExtraTreesClassifer methods (<xref rid="bib36" ref-type="bibr">Geurts et&#x000a0;al., 2006</xref>) gave the highest accuracy overall, and so were used here as a basis for comparing the accuracy of sequence-based filtering strategies for obtaining input features for neutralization predictions. The overall RF result is obtained by combining the results from each of the individual trees in the forest. For our RF experiments, we fixed the size of the ensemble to 250 trees but otherwise used default values of the scikit-learn parameters. In particular, the depth of the trees (<italic>i.e.,</italic> the number of branches) was adaptively determined using a bootstrap approach available in scikit-learn.</p><p id="p0280">As mentioned in the text, the three pre-filtering strategies used were: mRMR, the full signature set (including outside epitope signatures, hypervariable loop characteristics and clade associations), and only signatures in the bNAb epitopes. Input data files for signature-based prefiltering were created with columns of data translated so that clades, and signature amino acids and PNGSs in a given position, were assigned a 1 if associated with sensitivity, -1 if associated with resistance, or 0 if not associated. Quantitative values for correlated variable loop characteristics were also included.</p><p id="p0285">For each pre-filter strategy, we obtained predictions for two scenarios. First, we predicted IC<sub>50</sub> titers for the 207 Env sequences from the M group dataset 4, using leave-one-out cross-validation. We decided to use leave-one-out cross validation because the datasets were small enough that we were not computationally constrained, and this approach minimizes bias in small data sets (<xref rid="bib1" ref-type="bibr">Arlot&#x000a0;and Celisse, 2010</xref>). Second, we trained the RF on the M group data from datasets 1,2 and 4, and evaluated the performance on a holdout C clade virus set from dataset 3. To maintain the independence of our holdout set, we used signature pre-filters that were defined only on the basis of the M group datasets 1, 2, and 4, and we excluded the 26 pseudoviruses from the 200 in the C clade set that were also found in M group data. Predictions were made for the 13 bNAbs that were available in both dataset 3 and 4, and both regression (IC<sub>50</sub> titers; <xref rid="mmc1" ref-type="supplementary-material">Table S4</xref>; <xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref>) and classification (positive versus negative; <xref rid="mmc1" ref-type="supplementary-material">Table S5</xref>) prediction accuracies were assessed. We compared the accuracy of results using different strategies to pre-filter Env sequence alignment data.</p><p id="p0290">For regression, the aim is to predict the potency, and here we used three measures of performance to assess the quality of these predictions. The most direct measure is the mean absolute value of the prediction error (MAE). We also used the R<sup>2</sup> statistic (the coefficient of determination), whose variation is generally (but not strictly) bounded between zero and one, with larger values corresponding to better predictions. Finally, to assess the statistical significance of the predictions vis-a-vis a null hypothesis of no predictive power, we computed the p-value associated with a Kendall's tau test comparing the predictions to the true values. Ranked importance of different features from the RF analysis are provided in <xref rid="mmc3" ref-type="supplementary-material">Table S6</xref>.</p><p id="p0295">For classification, the goal is to predict a binary outcome of whether a bNAb will give detectable neutralization responses against a given sequence or not. The most intuitive measurement of performance is the accuracy, i.e., the fraction of sequences for which the prediction is correct. In some cases, however, simply predicting all positives or all negatives will give a very high accuracy score (e.g. 10E8 neutralizes at some level 98% of the viruses tested), so machine learning prediction is highly accurate, but it is not much better than just predicting that all Envs are positive.</p><p id="p0300">We tested 3 comparisons of particular interest to highlight the importance of signatures in enabling accurate predictions. First, we used only signature sites that were in contact residues versus the complete signatures; the complete list was favored for regression predictions (see Results). Second, we compared using signature sites sequence features as inputs, to using the mRMR approach to filter out the 100 most informative sites (<xref rid="bib40" ref-type="bibr">Hepler et&#x000a0;al., 2014</xref>, <xref rid="bib69" ref-type="bibr">Peng et&#x000a0;al., 2005</xref>). As noted in the Results, complete signatures yielded the most accurate predictions for regression, but there was no clear preference for classification. Before switching to our own mRMR-RF code, to make sure our approach was at least comparable in prediction accuracy to the previously published IDEpi classification code (<xref rid="bib40" ref-type="bibr">Hepler et&#x000a0;al., 2014</xref>), we compared the prediction accuracy of the two methods using 10-fold cross-validation for M group analysis, and also comparing the accuracy for the C clade holdout. Our implementation of the mRMR-RF approach was generally comparable to IDEpi (<xref rid="mmc1" ref-type="supplementary-material">Table S5</xref>), although for a small number of antibodies our error was substantially lower (e.g. VRC01 and 10E8). As a final comparison, because most published computational studies present only a very small number of amino acid signatures for each Ab, we sought to determine whether reducing the number of features to only the strongest features improved the scores, so we limited the Random Forest to include only the 3 most informative features. When comparing this restricted set to the full signature pattern, we found the restricted set not only did not improve classification or regression scores, it often made them much worse.</p></sec></sec><sec id="sec4.5.2"><title>Vaccine Immune Response Comparisons</title><sec id="sec4.5.2.1"><title>Analysis of SET vaccines neutralization data</title><p id="p0305">Neutralization data were analyzed using the R package (<ext-link ext-link-type="uri" xlink:href="https://www.r-project.org" id="intref0115">www.r-project.org</ext-link>) and GraphPad Prism version 6.00 software (GraphPad Software, San Diego California USA, <ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com" id="intref0120">www.graphpad.com</ext-link>&#x0201d;).</p><p id="p0310">We considered ID<sub>50</sub> titers positive if they were at least 10 above background:<list list-type="simple" id="ulist0015"><list-item id="u0030"><p id="p0315">Cutoff 1: Response&#x000a0;= Post, if Post &#x0003e; MuLV&#x000a0;+ 10; 10 otherwise, where &#x02018;Post&#x02019; is post-vaccination sera ID50 (4&#x000a0;weeks-post last vaccination), &#x02018;MuLV&#x02019; is the background level for an animal-matched MuLV negative control (4&#x000a0;weeks-post last vaccination) (<xref rid="bib11" ref-type="bibr">Bricault et&#x000a0;al, 2015</xref>), and &#x0201c;10&#x0201d; considered below the level of detection. We compared the statistical results presented in <xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref> with the outcome using alternative cutoffs 2 and 3:</p></list-item><list-item id="u0035"><p id="p0320">Cutoff 2: Response&#x000a0;= Post - MuLV, if Post-MuLV &#x0003e; 10, 10 otherwise,</p></list-item><list-item id="u0040"><p id="p0325">Cutoff 3: Response&#x000a0;= Post, if Post &#x0003e;3<sup>&#x02217;</sup>MuLV, 10 otherwise,</p></list-item></list></p><p id="p0330">and found the results obtained using Cutoff 2 and Cutoff 3 were consistent with the results obtained with the cutoff 1 when comparing vaccine groups, so Cutoff 1 is shown.</p><p id="p0335">The breadth of neutralization response (detected vs not-detected) was assessed by counting for each animal the proportion of pseudoviruses with detectable neutralization and then applying the two-sided Wilcoxon rank-sum test to compare the differences in distributions of responses per animal between the 459C WT and the V2-SET vaccines.</p><p id="p0340">The differences in the magnitude of responses between V2-SET vaccines and the 459C WT alone were assessed by a nonparametric permutation test following the strategy described in (<xref rid="bib65" ref-type="bibr">Parrish et&#x000a0;al., 2013</xref>). Briefly, this test compares the medians of responses elicited by the 459C WT and the given V2-SET vaccine in the observed data and in the 10,000 randomized sets of resampled data where the vaccine category is randomly reassigned between vaccinated animals. The fraction of occurrences of median differences in the randomized data that are equal to or less than that observed median differences in the actual data provides an estimate of the probability for observing the actual results by the chance alone.</p></sec></sec></sec><sec id="sec4.6"><title>Data and Software Availability</title><p id="p0345">In this study we have created a catalog of new signature sites, also including those that were defined previously, and created 3&#x000a0;web-based tools to facilitate future analyses: <italic>GenSig</italic> enables users to implement their own phylogenetically corrected signature analysis, <italic>FilteredForests</italic> enables machine learning predictions using either bNAb signature-based or mRMR prefilters, and we have automated neutralization signature predictions for new bNAb neutralization panels as they are incorporated into the Los Alamos HIV database <italic>CATNAP</italic> NAb interface (<xref rid="bib91" ref-type="bibr">Yoon et&#x000a0;al., 2015</xref>).</p><sec id="sec4.6.1"><title>GenSig</title><p id="p0350">We have developed a Signature Tool web interface, <italic>GenSig</italic>, at the Los Alamos HIV database: <ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/content/sequence/GENETICSIGNATURES/gs.html" id="intref0125">https://www.hiv.lanl.gov/content/sequence/GENETICSIGNATURES/gs.html</ext-link>. It can work on any phenotype file given in conjunction with a codon-aligned nucleotide alignment of a protein coding region of moderate size (&#x0003c;1000 gene sequences) -- the tool is not specific for HIV-1 and neutralization data. If, however, an input alignment is an HIV-1 gene alignment with the HXB2 reference sequence is included, the numbering of the output will be given according to HIV standardized HXB2 numbering.</p></sec><sec id="sec4.6.2"><title>CATNAP Enhancement</title><p id="p0355">The HIV-1 pseudovirus sequence data for the viral panels and previously published GenBank accession numbers are all already available through the Los Alamos HIV Database <italic>CATNAP</italic> tool, which we maintain. All new neutralization data used in this study will be integrated into the <italic>CATNAP</italic> tool at the time of publication: <ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/catnap" id="intref0130">https://www.hiv.lanl.gov/catnap</ext-link>. Since new HIV-1 bNAbs are continuously being added to the literature, and new neutralization panel data is regularly entered into the Los Alamos database <italic>CATNAP</italic> tool (<xref rid="bib91" ref-type="bibr">Yoon et&#x000a0;al., 2015</xref>) for comparative analysis (<ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/components/sequence/HIV/neutralization/index.html" id="intref0135">https://www.hiv.lanl.gov/components/sequence/HIV/neutralization/index.html</ext-link>), we have added an automated signature analysis feature to update signatures for new data as it accrues.</p></sec><sec id="sec4.6.3"><title>FilteredForests</title><p id="p0360">A web interface to run our sequence-based prefilters for machine learning predictions of bNAb sensitivity automatically coupled to RF code from the Python scikit-learn package, (<xref rid="bib67" ref-type="bibr">Pedregosa et&#x000a0;al., 2011</xref>) is called <italic>FilteredForests</italic> code. One can generate their own signature-based prefilters or use mRMR (<xref rid="bib69" ref-type="bibr">Peng et&#x000a0;al., 2005</xref>) to generate from a sequence alignment input files for the RF machine learning codes ExtraTreesRegressor and ExtraTreesClassifer. This web interface is available at: <ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/content/sequence/FLTFORESTS/fltforests.html" id="intref0140">https://www.hiv.lanl.gov/content/sequence/FLTFORESTS/fltforests.html</ext-link></p><p id="p0365">The code is available at:<ext-link ext-link-type="uri" xlink:href="https://github.com/hivdb-lanl/FilteredForests" id="intref0145">https://github.com/hivdb-lanl/FilteredForests</ext-link></p></sec><sec id="sec4.6.4"><title>bNAb signature information access</title><p id="p0370">To enable comparisons to sites of interest for particular bNAbs identified here, to sites identified in the previously published literature, all signatures identified in this study have been incorporated into the Los Alamos HIV Immunology Databases. The signature information will be included and accessible through three Los Alamos database tools: a simple spread sheet that is an overview of&#x000a0;many of the key findings from the literature, that allows comparisons of findings for all sites (rows) in Env across many&#x000a0;antibody&#x000a0;studies, organized by paper and/or antibody (columns) (<ext-link ext-link-type="uri" xlink:href="https://www.hiv.lanl.gov/content/immunology/neutralizing_ab_resources.html" id="intref0150">https://www.hiv.lanl.gov/content/immunology/neutralizing_ab_resources.html</ext-link>). The signatures will also be accessible through the relational database we have built for searching bNAb characteristics (Neutralizing Antibody Contexts and Features, (<ext-link ext-link-type="uri" xlink:href="http://www.hiv.lanl.gov/components/sequence/HIV/featuredb/search/env_ab_search_pub.comp" id="intref0155">www.hiv.lanl.gov/components/sequence/HIV/featuredb/search/env_ab_search_pub.comp</ext-link>); and the Genome Browser, which allows users to interactively explore functional domains and sites relevant to antibodies across Env (<ext-link ext-link-type="uri" xlink:href="http://www.hiv.lanl.gov/content/sequence/genome_browser/browser.html" id="intref0160">www.hiv.lanl.gov/content/sequence/genome_browser/browser.html</ext-link>).&#x0201d;</p></sec></sec></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Arlot</surname><given-names>S.</given-names></name><name><surname>Celisse</surname><given-names>A.</given-names></name></person-group><article-title>A survey of cross-validation procedures for model selection</article-title><source>Statist. Surv.</source><volume>4</volume><year>2010</year><fpage>40</fpage><lpage>79</lpage></element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Behrens</surname><given-names>A.J.</given-names></name><name><surname>Vasiljevic</surname><given-names>S.</given-names></name><name><surname>Pritchard</surname><given-names>L.K.</given-names></name><name><surname>Harvey</surname><given-names>D.J.</given-names></name><name><surname>Andev</surname><given-names>R.S.</given-names></name><name><surname>Krumm</surname><given-names>S.A.</given-names></name><name><surname>Struwe</surname><given-names>W.B.</given-names></name><name><surname>Cupo</surname><given-names>A.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Zitzmann</surname><given-names>N.</given-names></name></person-group><article-title>Composition and antigenic effects of individual glycan sites of a trimeric HIV-1 envelope glycoprotein</article-title><source>Cell Rep.</source><volume>14</volume><year>2016</year><fpage>2695</fpage><lpage>2706</lpage><pub-id pub-id-type="pmid">26972002</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Bhattacharya</surname><given-names>T.</given-names></name><name><surname>Daniels</surname><given-names>M.</given-names></name><name><surname>Heckerman</surname><given-names>D.</given-names></name><name><surname>Foley</surname><given-names>B.</given-names></name><name><surname>Frahm</surname><given-names>N.</given-names></name><name><surname>Kadie</surname><given-names>C.</given-names></name><name><surname>Carlson</surname><given-names>J.</given-names></name><name><surname>Yusim</surname><given-names>K.</given-names></name><name><surname>McMahon</surname><given-names>B.</given-names></name><name><surname>Gaschen</surname><given-names>B.</given-names></name></person-group><article-title>Founder effects in the assessment of HIV polymorphisms and HLA allele associations</article-title><source>Science</source><volume>315</volume><year>2007</year><fpage>1583</fpage><lpage>1586</lpage><pub-id pub-id-type="pmid">17363674</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Bonsignori</surname><given-names>M.</given-names></name><name><surname>Hwang</surname><given-names>K.K.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Tsao</surname><given-names>C.Y.</given-names></name><name><surname>Morris</surname><given-names>L.</given-names></name><name><surname>Gray</surname><given-names>E.</given-names></name><name><surname>Marshall</surname><given-names>D.J.</given-names></name><name><surname>Crump</surname><given-names>J.A.</given-names></name><name><surname>Kapiga</surname><given-names>S.H.</given-names></name><name><surname>Sam</surname><given-names>N.E.</given-names></name></person-group><article-title>Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors</article-title><source>J.&#x000a0;Virol.</source><volume>85</volume><year>2011</year><fpage>9998</fpage><lpage>10009</lpage><pub-id pub-id-type="pmid">21795340</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Bonsignori</surname><given-names>M.</given-names></name><name><surname>Kreider</surname><given-names>E.F.</given-names></name><name><surname>Fera</surname><given-names>D.</given-names></name><name><surname>Meyerhoff</surname><given-names>R.R.</given-names></name><name><surname>Bradley</surname><given-names>T.</given-names></name><name><surname>Wiehe</surname><given-names>K.</given-names></name><name><surname>Alam</surname><given-names>S.M.</given-names></name><name><surname>Aussedat</surname><given-names>B.</given-names></name><name><surname>Walkowicz</surname><given-names>W.E.</given-names></name><name><surname>Hwang</surname><given-names>K.K.</given-names></name></person-group><article-title>Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies</article-title><source>Sci. Transl. Med.</source><volume>9</volume><year>2017</year></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Bonsignori</surname><given-names>M.</given-names></name><name><surname>Liao</surname><given-names>H.X.</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Williams</surname><given-names>W.B.</given-names></name><name><surname>Alam</surname><given-names>S.M.</given-names></name><name><surname>Montefiori</surname><given-names>D.C.</given-names></name><name><surname>Haynes</surname><given-names>B.F.</given-names></name></person-group><article-title>Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development</article-title><source>Immunol. Rev.</source><volume>275</volume><year>2017</year><fpage>145</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">28133802</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Bonsignori</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>Sheng</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Joyce</surname><given-names>M.G.</given-names></name><name><surname>Ozorowski</surname><given-names>G.</given-names></name><name><surname>Chuang</surname><given-names>G.Y.</given-names></name><name><surname>Schramm</surname><given-names>C.A.</given-names></name><name><surname>Wiehe</surname><given-names>K.</given-names></name></person-group><article-title>Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody</article-title><source>Cell</source><volume>165</volume><year>2016</year><fpage>449</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">26949186</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>T.</given-names></name><name><surname>Trama</surname><given-names>A.</given-names></name><name><surname>Tumba</surname><given-names>N.</given-names></name><name><surname>Gray</surname><given-names>E.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Madani</surname><given-names>N.</given-names></name><name><surname>Jahanbakhsh</surname><given-names>F.</given-names></name><name><surname>Eaton</surname><given-names>A.</given-names></name><name><surname>Xia</surname><given-names>S.M.</given-names></name><name><surname>Parks</surname><given-names>R.</given-names></name></person-group><article-title>Amino acid changes in the HIV-1 gp41 membrane proximal region control virus neutralization sensitivity</article-title><source>EBioMedicine</source><volume>12</volume><year>2016</year><fpage>196</fpage><lpage>207</lpage><pub-id pub-id-type="pmid">27612593</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Breiman</surname><given-names>L.</given-names></name></person-group><article-title>Random forests</article-title><source>Mach. Learn.</source><volume>45</volume><year>2001</year><fpage>5</fpage><lpage>32</lpage></element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Bricault</surname><given-names>C.A.</given-names></name><name><surname>Kovacs</surname><given-names>J.M.</given-names></name><name><surname>Badamchi-Zadeh</surname><given-names>A.</given-names></name><name><surname>McKee</surname><given-names>K.</given-names></name><name><surname>Shields</surname><given-names>J.L.</given-names></name><name><surname>Gunn</surname><given-names>B.M.</given-names></name><name><surname>Neubauer</surname><given-names>G.H.</given-names></name><name><surname>Ghantous</surname><given-names>F.</given-names></name><name><surname>Jennings</surname><given-names>J.</given-names></name><name><surname>Gillis</surname><given-names>L.</given-names></name></person-group><article-title>Neutralizing antibody responses following long-term vaccination with HIV-1 Env gp140 in guinea pigs</article-title><source>J.&#x000a0;Virol.</source><volume>92</volume><year>2018</year></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Bricault</surname><given-names>C.A.</given-names></name><name><surname>Kovacs</surname><given-names>J.M.</given-names></name><name><surname>Nkolola</surname><given-names>J.P.</given-names></name><name><surname>Yusim</surname><given-names>K.</given-names></name><name><surname>Giorgi</surname><given-names>E.E.</given-names></name><name><surname>Shields</surname><given-names>J.L.</given-names></name><name><surname>Perry</surname><given-names>J.</given-names></name><name><surname>Lavine</surname><given-names>C.L.</given-names></name><name><surname>Cheung</surname><given-names>A.</given-names></name><name><surname>Ellingson-Strouss</surname><given-names>K.</given-names></name></person-group><article-title>A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component</article-title><source>J.&#x000a0;Virol.</source><volume>89</volume><year>2015</year><fpage>2507</fpage><lpage>2519</lpage><pub-id pub-id-type="pmid">25540368</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Buchacher</surname><given-names>A.</given-names></name><name><surname>Predl</surname><given-names>R.</given-names></name><name><surname>Strutzenberger</surname><given-names>K.</given-names></name><name><surname>Steinfellner</surname><given-names>W.</given-names></name><name><surname>Trkola</surname><given-names>A.</given-names></name><name><surname>Purtscher</surname><given-names>M.</given-names></name><name><surname>Gruber</surname><given-names>G.</given-names></name><name><surname>Tauer</surname><given-names>C.</given-names></name><name><surname>Steindl</surname><given-names>F.</given-names></name><name><surname>Jungbauer</surname><given-names>A.</given-names></name></person-group><article-title>Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization</article-title><source>AIDS Res. Hum. Retrovir.</source><volume>10</volume><year>1994</year><fpage>359</fpage><lpage>369</lpage><pub-id pub-id-type="pmid">7520721</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>D.R.</given-names></name><name><surname>Barbas</surname><given-names>C.F.</given-names><suffix>3rd</suffix></name><name><surname>Persson</surname><given-names>M.A.</given-names></name><name><surname>Koenig</surname><given-names>S.</given-names></name><name><surname>Chanock</surname><given-names>R.M.</given-names></name><name><surname>Lerner</surname><given-names>R.A.</given-names></name></person-group><article-title>A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>88</volume><year>1991</year><fpage>10134</fpage><lpage>10137</lpage><pub-id pub-id-type="pmid">1719545</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>D.R.</given-names></name><name><surname>Hangartner</surname><given-names>L.</given-names></name></person-group><article-title>Broadly neutralizing antibodies to HIV and their role in vaccine design</article-title><source>Annu. Rev. Immunol.</source><volume>34</volume><year>2016</year><fpage>635</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">27168247</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>D.R.</given-names></name><name><surname>Mascola</surname><given-names>J.R.</given-names></name></person-group><article-title>Antibody responses to envelope glycoproteins in HIV-1 infection</article-title><source>Nat. Immunol.</source><volume>16</volume><year>2015</year><fpage>571</fpage><lpage>576</lpage><pub-id pub-id-type="pmid">25988889</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal" id="sref95"><person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>R.M.</given-names></name><name><surname>Zwick</surname><given-names>M.B.</given-names></name><name><surname>Stanfield</surname><given-names>R.L.</given-names></name><name><surname>Kunert</surname><given-names>R.</given-names></name><name><surname>Binley</surname><given-names>J.M.</given-names></name><name><surname>Katinger</surname><given-names>H.</given-names></name><name><surname>Burton</surname><given-names>D.R.</given-names></name><name><surname>Wilson</surname><given-names>I.A.</given-names></name></person-group><article-title>Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41</article-title><source>Immunity</source><volume>22</volume><year>2005</year><fpage>163</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">15723805</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Chuang</surname><given-names>G.Y.</given-names></name><name><surname>Acharya</surname><given-names>P.</given-names></name><name><surname>Schmidt</surname><given-names>S.D.</given-names></name><name><surname>Yang</surname><given-names>Y.</given-names></name><name><surname>Louder</surname><given-names>M.K.</given-names></name><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>Kwon</surname><given-names>Y.D.</given-names></name><name><surname>Pancera</surname><given-names>M.</given-names></name><name><surname>Bailer</surname><given-names>R.T.</given-names></name><name><surname>Doria-Rose</surname><given-names>N.A.</given-names></name></person-group><article-title>Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains</article-title><source>J.&#x000a0;Virol.</source><volume>87</volume><year>2013</year><fpage>10047</fpage><lpage>10058</lpage><pub-id pub-id-type="pmid">23843642</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Chuang</surname><given-names>G.Y.</given-names></name><name><surname>Liou</surname><given-names>D.</given-names></name><name><surname>Kwong</surname><given-names>P.D.</given-names></name><name><surname>Georgiev</surname><given-names>I.S.</given-names></name></person-group><article-title>NEP: web server for epitope prediction based on antibody neutralization of viral strains with diverse sequences</article-title><source>Nucleic Acids Res.</source><volume>42</volume><year>2014</year><fpage>W64</fpage><lpage>W71</lpage><pub-id pub-id-type="pmid">24782517</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>D.</given-names></name><name><surname>Langedijk</surname><given-names>J.P.</given-names></name><name><surname>Hinz</surname><given-names>A.</given-names></name><name><surname>Seaman</surname><given-names>M.S.</given-names></name><name><surname>Vanzetta</surname><given-names>F.</given-names></name><name><surname>Fernandez-Rodriguez</surname><given-names>B.M.</given-names></name><name><surname>Silacci</surname><given-names>C.</given-names></name><name><surname>Pinna</surname><given-names>D.</given-names></name><name><surname>Jarrossay</surname><given-names>D.</given-names></name><name><surname>Balla-Jhagjhoorsingh</surname><given-names>S.</given-names></name></person-group><article-title>Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals</article-title><source>PLoS One</source><volume>5</volume><year>2010</year><fpage>e8805</fpage><pub-id pub-id-type="pmid">20098712</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Crispin</surname><given-names>M.</given-names></name><name><surname>Doores</surname><given-names>K.J.</given-names></name></person-group><article-title>Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design</article-title><source>Curr. Opin. Virol.</source><volume>11</volume><year>2015</year><fpage>63</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">25747313</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Crooks</surname><given-names>G.E.</given-names></name><name><surname>Hon</surname><given-names>G.</given-names></name><name><surname>Chandonia</surname><given-names>J.M.</given-names></name><name><surname>Brenner</surname><given-names>S.E.</given-names></name></person-group><article-title>WebLogo: a sequence logo generator</article-title><source>Genome Res.</source><volume>14</volume><year>2004</year><fpage>1188</fpage><lpage>1190</lpage><pub-id pub-id-type="pmid">15173120</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="other" id="sref21"><person-group person-group-type="author"><name><surname>Dabney</surname><given-names>A.</given-names></name><name><surname>Storey</surname><given-names>J.D.</given-names></name></person-group><article-title>Q-value estimation for false discovery rate control. R package version 2.14.0</article-title><ext-link ext-link-type="uri" xlink:href="http://github.com/jdstorey/qvalue" id="intref0170">http://github.com/jdstorey/qvalue</ext-link><year>2013</year></element-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>deCamp</surname><given-names>A.</given-names></name><name><surname>Hraber</surname><given-names>P.</given-names></name><name><surname>Bailer</surname><given-names>R.T.</given-names></name><name><surname>Seaman</surname><given-names>M.S.</given-names></name><name><surname>Ochsenbauer</surname><given-names>C.</given-names></name><name><surname>Kappes</surname><given-names>J.</given-names></name><name><surname>Gottardo</surname><given-names>R.</given-names></name><name><surname>Edlefsen</surname><given-names>P.</given-names></name><name><surname>Self</surname><given-names>S.</given-names></name><name><surname>Tang</surname><given-names>H.</given-names></name></person-group><article-title>Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies</article-title><source>J.&#x000a0;Virol.</source><volume>88</volume><year>2014</year><fpage>2489</fpage><lpage>2507</lpage><pub-id pub-id-type="pmid">24352443</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Derdeyn</surname><given-names>C.A.</given-names></name><name><surname>Decker</surname><given-names>J.M.</given-names></name><name><surname>Bibollet-Ruche</surname><given-names>F.</given-names></name><name><surname>Mokili</surname><given-names>J.L.</given-names></name><name><surname>Muldoon</surname><given-names>M.</given-names></name><name><surname>Denham</surname><given-names>S.A.</given-names></name><name><surname>Heil</surname><given-names>M.L.</given-names></name><name><surname>Kasolo</surname><given-names>F.</given-names></name><name><surname>Musonda</surname><given-names>R.</given-names></name><name><surname>Hahn</surname><given-names>B.H.</given-names></name></person-group><article-title>Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission</article-title><source>Science</source><volume>303</volume><year>2004</year><fpage>2019</fpage><lpage>2022</lpage><pub-id pub-id-type="pmid">15044802</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Diskin</surname><given-names>R.</given-names></name><name><surname>Scheid</surname><given-names>J.F.</given-names></name><name><surname>Marcovecchio</surname><given-names>P.M.</given-names></name><name><surname>West</surname><given-names>A.P.</given-names><suffix>Jr.</suffix></name><name><surname>Klein</surname><given-names>F.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Gnanapragasam</surname><given-names>P.N.</given-names></name><name><surname>Abadir</surname><given-names>A.</given-names></name><name><surname>Seaman</surname><given-names>M.S.</given-names></name><name><surname>Nussenzweig</surname><given-names>M.C.</given-names></name></person-group><article-title>Increasing the potency and breadth of an HIV antibody by using structure-based rational design</article-title><source>Science</source><volume>334</volume><year>2011</year><fpage>1289</fpage><lpage>1293</lpage><pub-id pub-id-type="pmid">22033520</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Doria-Rose</surname><given-names>N.A.</given-names></name><name><surname>Bhiman</surname><given-names>J.N.</given-names></name><name><surname>Roark</surname><given-names>R.S.</given-names></name><name><surname>Schramm</surname><given-names>C.A.</given-names></name><name><surname>Gorman</surname><given-names>J.</given-names></name><name><surname>Chuang</surname><given-names>G.Y.</given-names></name><name><surname>Pancera</surname><given-names>M.</given-names></name><name><surname>Cale</surname><given-names>E.M.</given-names></name><name><surname>Ernandes</surname><given-names>M.J.</given-names></name><name><surname>Louder</surname><given-names>M.K.</given-names></name></person-group><article-title>New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency</article-title><source>J.&#x000a0;Virol.</source><volume>90</volume><year>2016</year><fpage>76</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">26468542</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Doria-Rose</surname><given-names>N.A.</given-names></name><name><surname>Georgiev</surname><given-names>I.</given-names></name><name><surname>O'Dell</surname><given-names>S.</given-names></name><name><surname>Chuang</surname><given-names>G.Y.</given-names></name><name><surname>Staupe</surname><given-names>R.P.</given-names></name><name><surname>McLellan</surname><given-names>J.S.</given-names></name><name><surname>Gorman</surname><given-names>J.</given-names></name><name><surname>Pancera</surname><given-names>M.</given-names></name><name><surname>Bonsignori</surname><given-names>M.</given-names></name><name><surname>Haynes</surname><given-names>B.F.</given-names></name></person-group><article-title>A short segment of the HIV-1 gp120 V1/V2 region is a major determinant of resistance to V1/V2 neutralizing antibodies</article-title><source>J.&#x000a0;Virol.</source><volume>86</volume><year>2012</year><fpage>8319</fpage><lpage>8323</lpage><pub-id pub-id-type="pmid">22623764</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Doria-Rose</surname><given-names>N.A.</given-names></name><name><surname>Schramm</surname><given-names>C.A.</given-names></name><name><surname>Gorman</surname><given-names>J.</given-names></name><name><surname>Moore</surname><given-names>P.L.</given-names></name><name><surname>Bhiman</surname><given-names>J.N.</given-names></name><name><surname>DeKosky</surname><given-names>B.J.</given-names></name><name><surname>Ernandes</surname><given-names>M.J.</given-names></name><name><surname>Georgiev</surname><given-names>I.S.</given-names></name><name><surname>Kim</surname><given-names>H.J.</given-names></name><name><surname>Pancera</surname><given-names>M.</given-names></name></person-group><article-title>Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies</article-title><source>Nature</source><volume>509</volume><year>2014</year><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">24590074</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Escolano</surname><given-names>A.</given-names></name><name><surname>Steichen</surname><given-names>J.M.</given-names></name><name><surname>Dosenovic</surname><given-names>P.</given-names></name><name><surname>Kulp</surname><given-names>D.W.</given-names></name><name><surname>Golijanin</surname><given-names>J.</given-names></name><name><surname>Sok</surname><given-names>D.</given-names></name><name><surname>Freund</surname><given-names>N.T.</given-names></name><name><surname>Gitlin</surname><given-names>A.D.</given-names></name><name><surname>Oliveira</surname><given-names>T.</given-names></name><name><surname>Araki</surname><given-names>T.</given-names></name></person-group><article-title>Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knockin mice</article-title><source>Cell</source><volume>166</volume><year>2016</year><fpage>1445</fpage><lpage>1458.e12</lpage><pub-id pub-id-type="pmid">27610569</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>M.C.</given-names></name><name><surname>Phung</surname><given-names>P.</given-names></name><name><surname>Paquet</surname><given-names>A.C.</given-names></name><name><surname>Parikh</surname><given-names>A.</given-names></name><name><surname>Petropoulos</surname><given-names>C.J.</given-names></name><name><surname>Wrin</surname><given-names>T.</given-names></name><name><surname>Haddad</surname><given-names>M.</given-names></name></person-group><article-title>Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method</article-title><source>BMC Bioinformatics</source><volume>15</volume><year>2014</year><fpage>77</fpage><pub-id pub-id-type="pmid">24646213</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Fera</surname><given-names>D.</given-names></name><name><surname>Schmidt</surname><given-names>A.G.</given-names></name><name><surname>Haynes</surname><given-names>B.F.</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Liao</surname><given-names>H.X.</given-names></name><name><surname>Kepler</surname><given-names>T.B.</given-names></name><name><surname>Harrison</surname><given-names>S.C.</given-names></name></person-group><article-title>Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains</article-title><source>Proc. Natl. Acad Sci. USA</source><volume>111</volume><year>2014</year><fpage>10275</fpage><lpage>10280</lpage><pub-id pub-id-type="pmid">24982157</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>A.L.</given-names></name><name><surname>Falkowska</surname><given-names>E.</given-names></name><name><surname>Walker</surname><given-names>L.M.</given-names></name><name><surname>Seaman</surname><given-names>M.S.</given-names></name><name><surname>Burton</surname><given-names>D.R.</given-names></name><name><surname>Chakraborty</surname><given-names>A.K.</given-names></name></person-group><article-title>Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity data</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><fpage>e80562</fpage><pub-id pub-id-type="pmid">24312481</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>M.M.</given-names></name><name><surname>Seaman</surname><given-names>M.S.</given-names></name><name><surname>Rits-Volloch</surname><given-names>S.</given-names></name><name><surname>Hong</surname><given-names>X.</given-names></name><name><surname>Kao</surname><given-names>C.Y.</given-names></name><name><surname>Ho</surname><given-names>D.D.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name></person-group><article-title>Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody</article-title><source>Structure</source><volume>18</volume><year>2010</year><fpage>1632</fpage><lpage>1641</lpage><pub-id pub-id-type="pmid">21134642</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Frey</surname><given-names>G.</given-names></name><name><surname>Peng</surname><given-names>H.</given-names></name><name><surname>Rits-Volloch</surname><given-names>S.</given-names></name><name><surname>Morelli</surname><given-names>M.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name></person-group><article-title>A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>105</volume><year>2008</year><fpage>3739</fpage><lpage>3744</lpage><pub-id pub-id-type="pmid">18322015</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Bonsignori</surname><given-names>M.</given-names></name><name><surname>Liao</surname><given-names>H.X.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Xia</surname><given-names>S.M.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Cai</surname><given-names>F.</given-names></name><name><surname>Hwang</surname><given-names>K.K.</given-names></name><name><surname>Song</surname><given-names>H.</given-names></name><name><surname>Zhou</surname><given-names>T.</given-names></name></person-group><article-title>Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies</article-title><source>Cell</source><volume>158</volume><year>2014</year><fpage>481</fpage><lpage>491</lpage><pub-id pub-id-type="pmid">25065977</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Garces</surname><given-names>F.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>de Val</surname><given-names>N.</given-names></name><name><surname>Torrents de la Pena</surname><given-names>A.T.</given-names></name><name><surname>Kong</surname><given-names>L.</given-names></name><name><surname>Puchades</surname><given-names>C.</given-names></name><name><surname>Hua</surname><given-names>Y.</given-names></name><name><surname>Stanfield</surname><given-names>R.L.</given-names></name><name><surname>Burton</surname><given-names>D.R.</given-names></name><name><surname>Moore</surname><given-names>J.P.</given-names></name></person-group><article-title>Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans</article-title><source>Immunity</source><volume>43</volume><year>2015</year><fpage>1053</fpage><lpage>1063</lpage><pub-id pub-id-type="pmid">26682982</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Geurts</surname><given-names>P.</given-names></name><name><surname>Ernst</surname><given-names>D.</given-names></name><name><surname>Wehenkel</surname><given-names>L.</given-names></name></person-group><article-title>Extremely randomized trees</article-title><source>Mach. Learn.</source><volume>63</volume><year>2006</year><fpage>3</fpage><lpage>42</lpage></element-citation></ref><ref id="bib37"><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Gnanakaran</surname><given-names>S.</given-names></name><name><surname>Daniels</surname><given-names>M.G.</given-names></name><name><surname>Bhattacharya</surname><given-names>T.</given-names></name><name><surname>Lapedes</surname><given-names>A.S.</given-names></name><name><surname>Sethi</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Tang</surname><given-names>H.</given-names></name><name><surname>Greene</surname><given-names>K.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Haynes</surname><given-names>B.F.</given-names></name></person-group><article-title>Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies</article-title><source>PLoS Comp. Biol.</source><volume>6</volume><year>2010</year><fpage>e1000955</fpage></element-citation></ref><ref id="bib38"><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Gorman</surname><given-names>J.</given-names></name><name><surname>Soto</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>M.M.</given-names></name><name><surname>Davenport</surname><given-names>T.M.</given-names></name><name><surname>Guttman</surname><given-names>M.</given-names></name><name><surname>Bailer</surname><given-names>R.T.</given-names></name><name><surname>Chambers</surname><given-names>M.</given-names></name><name><surname>Chuang</surname><given-names>G.Y.</given-names></name><name><surname>DeKosky</surname><given-names>B.J.</given-names></name><name><surname>Doria-Rose</surname><given-names>N.A.</given-names></name></person-group><article-title>Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design</article-title><source>Nat. Struct. Mol. Biol.</source><volume>23</volume><year>2016</year><fpage>81</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">26689967</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Guindon</surname><given-names>S.</given-names></name><name><surname>Dufayard</surname><given-names>J.F.</given-names></name><name><surname>Lefort</surname><given-names>V.</given-names></name><name><surname>Anisimova</surname><given-names>M.</given-names></name><name><surname>Hordijk</surname><given-names>W.</given-names></name><name><surname>Gascuel</surname><given-names>O.</given-names></name></person-group><article-title>New algorithms and methods to estimate maximum-likelihood&#x000a0;phylogenies: assessing the performance of PhyML 3.0</article-title><source>Syst. Biol.</source><volume>59</volume><year>2010</year><fpage>307</fpage><lpage>321</lpage><pub-id pub-id-type="pmid">20525638</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Hepler</surname><given-names>N.L.</given-names></name><name><surname>Scheffler</surname><given-names>K.</given-names></name><name><surname>Weaver</surname><given-names>S.</given-names></name><name><surname>Murrell</surname><given-names>B.</given-names></name><name><surname>Richman</surname><given-names>D.D.</given-names></name><name><surname>Burton</surname><given-names>D.R.</given-names></name><name><surname>Poignard</surname><given-names>P.</given-names></name><name><surname>Smith</surname><given-names>D.M.</given-names></name><name><surname>Kosakovsky Pond</surname><given-names>S.L.</given-names></name></person-group><article-title>IDEPI: rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platform</article-title><source>PLoS Comput. Biol.</source><volume>10</volume><year>2014</year><fpage>e1003842</fpage><pub-id pub-id-type="pmid">25254639</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Hraber</surname><given-names>P.</given-names></name><name><surname>Korber</surname><given-names>B.T.</given-names></name><name><surname>Lapedes</surname><given-names>A.S.</given-names></name><name><surname>Bailer</surname><given-names>R.T.</given-names></name><name><surname>Seaman</surname><given-names>M.S.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Greene</surname><given-names>K.M.</given-names></name><name><surname>McCutchan</surname><given-names>F.</given-names></name><name><surname>Williamson</surname><given-names>C.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name></person-group><article-title>Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies</article-title><source>J.&#x000a0;Virol.</source><volume>88</volume><year>2014</year><fpage>12623</fpage><lpage>12643</lpage><pub-id pub-id-type="pmid">25142591</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Hraber</surname><given-names>P.</given-names></name><name><surname>Seaman</surname><given-names>M.S.</given-names></name><name><surname>Bailer</surname><given-names>R.T.</given-names></name><name><surname>Mascola</surname><given-names>J.R.</given-names></name><name><surname>Montefiori</surname><given-names>D.C.</given-names></name><name><surname>Korber</surname><given-names>B.T.</given-names></name></person-group><article-title>Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection</article-title><source>AIDS</source><volume>28</volume><year>2014</year><fpage>163</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">24361678</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Kang</surname><given-names>B.H.</given-names></name><name><surname>Ishida</surname><given-names>E.</given-names></name><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>Griesman</surname><given-names>T.</given-names></name><name><surname>Sheng</surname><given-names>Z.</given-names></name><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Doria-Rose</surname><given-names>N.A.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>McKee</surname><given-names>K.</given-names></name></person-group><article-title>Identification of a CD4-Binding-Site antibody to HIV that evolved near-pan neutralization breadth</article-title><source>Immunity</source><volume>45</volume><year>2016</year><fpage>1108</fpage><lpage>1121</lpage><pub-id pub-id-type="pmid">27851912</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Ofek</surname><given-names>G.</given-names></name><name><surname>Laub</surname><given-names>L.</given-names></name><name><surname>Louder</surname><given-names>M.K.</given-names></name><name><surname>Doria-Rose</surname><given-names>N.A.</given-names></name><name><surname>Longo</surname><given-names>N.S.</given-names></name><name><surname>Imamichi</surname><given-names>H.</given-names></name><name><surname>Bailer</surname><given-names>R.T.</given-names></name><name><surname>Chakrabarti</surname><given-names>B.</given-names></name><name><surname>Sharma</surname><given-names>S.K.</given-names></name></person-group><article-title>Broad and potent neutralization of HIV-1 by a gp41-specific human antibody</article-title><source>Nature</source><volume>491</volume><year>2012</year><fpage>406</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">23151583</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Julien</surname><given-names>J.P.</given-names></name><name><surname>Sok</surname><given-names>D.</given-names></name><name><surname>Khayat</surname><given-names>R.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Doores</surname><given-names>K.J.</given-names></name><name><surname>Walker</surname><given-names>L.M.</given-names></name><name><surname>Ramos</surname><given-names>A.</given-names></name><name><surname>Diwanji</surname><given-names>D.C.</given-names></name><name><surname>Pejchal</surname><given-names>R.</given-names></name><name><surname>Cupo</surname><given-names>A.</given-names></name></person-group><article-title>Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans</article-title><source>PLoS Pathog.</source><volume>9</volume><year>2013</year><fpage>e1003342</fpage><pub-id pub-id-type="pmid">23658524</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Kayman</surname><given-names>S.C.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Revesz</surname><given-names>K.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Kopelman</surname><given-names>R.</given-names></name><name><surname>Pinter</surname><given-names>A.</given-names></name></person-group><article-title>Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains</article-title><source>J.&#x000a0;Virol.</source><volume>68</volume><year>1994</year><fpage>400</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">7504740</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>F.</given-names></name><name><surname>Diskin</surname><given-names>R.</given-names></name><name><surname>Scheid</surname><given-names>J.F.</given-names></name><name><surname>Gaebler</surname><given-names>C.</given-names></name><name><surname>Mouquet</surname><given-names>H.</given-names></name><name><surname>Georgiev</surname><given-names>I.S.</given-names></name><name><surname>Pancera</surname><given-names>M.</given-names></name><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>Incesu</surname><given-names>R.B.</given-names></name><name><surname>Fu</surname><given-names>B.Z.</given-names></name></person-group><article-title>Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization</article-title><source>Cell</source><volume>153</volume><year>2013</year><fpage>126</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">23540694</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>F.</given-names></name><name><surname>Gaebler</surname><given-names>C.</given-names></name><name><surname>Mouquet</surname><given-names>H.</given-names></name><name><surname>Sather</surname><given-names>D.N.</given-names></name><name><surname>Lehmann</surname><given-names>C.</given-names></name><name><surname>Scheid</surname><given-names>J.F.</given-names></name><name><surname>Kraft</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Pietzsch</surname><given-names>J.</given-names></name><name><surname>Hurley</surname><given-names>A.</given-names></name></person-group><article-title>Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein</article-title><source>J.&#x000a0;Exp. Med.</source><volume>209</volume><year>2012</year><fpage>1469</fpage><lpage>1479</lpage><pub-id pub-id-type="pmid">22826297</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>L.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Doores</surname><given-names>K.J.</given-names></name><name><surname>Murin</surname><given-names>C.D.</given-names></name><name><surname>Julien</surname><given-names>J.P.</given-names></name><name><surname>McBride</surname><given-names>R.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Marozsan</surname><given-names>A.</given-names></name><name><surname>Cupo</surname><given-names>A.</given-names></name><name><surname>Klasse</surname><given-names>P.J.</given-names></name></person-group><article-title>Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120</article-title><source>Nat. Struct. Mol. Biol.</source><volume>20</volume><year>2013</year><fpage>796</fpage><lpage>803</lpage><pub-id pub-id-type="pmid">23708606</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Korber</surname><given-names>B.</given-names></name><name><surname>Hraber</surname><given-names>P.</given-names></name><name><surname>Wagh</surname><given-names>K.</given-names></name><name><surname>Hahn</surname><given-names>B.H.</given-names></name></person-group><article-title>Polyvalent vaccine approaches to combat HIV-1 diversity</article-title><source>Immunol. Rev.</source><volume>275</volume><year>2017</year><fpage>230</fpage><lpage>244</lpage><pub-id pub-id-type="pmid">28133800</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Korber</surname><given-names>B.</given-names></name><name><surname>Muldoon</surname><given-names>M.</given-names></name><name><surname>Theiler</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Gupta</surname><given-names>R.</given-names></name><name><surname>Lapedes</surname><given-names>A.</given-names></name><name><surname>Hahn</surname><given-names>B.H.</given-names></name><name><surname>Wolinsky</surname><given-names>S.</given-names></name><name><surname>Bhattacharya</surname><given-names>T.</given-names></name></person-group><article-title>Timing the ancestor of the HIV-1 pandemic strains</article-title><source>Science</source><volume>288</volume><year>2000</year><fpage>1789</fpage><lpage>1796</lpage><pub-id pub-id-type="pmid">10846155</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Korber</surname><given-names>B.T.</given-names></name><name><surname>Letvin</surname><given-names>N.L.</given-names></name><name><surname>Haynes</surname><given-names>B.F.</given-names></name></person-group><article-title>T-cell vaccine strategies for human immunodeficiency virus, the virus with a thousand faces</article-title><source>J.&#x000a0;Virol.</source><volume>83</volume><year>2009</year><fpage>8300</fpage><lpage>8314</lpage><pub-id pub-id-type="pmid">19439471</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Kwong</surname><given-names>P.D.</given-names></name><name><surname>Wyatt</surname><given-names>R.</given-names></name><name><surname>Robinson</surname><given-names>J.</given-names></name><name><surname>Sweet</surname><given-names>R.W.</given-names></name><name><surname>Sodroski</surname><given-names>J.</given-names></name><name><surname>Hendrickson</surname><given-names>W.A.</given-names></name></person-group><article-title>Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody</article-title><source>Nature</source><volume>393</volume><year>1998</year><fpage>648</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">9641677</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal" id="sref96"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M.</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Mascola</surname><given-names>J.R.</given-names></name><name><surname>Stamatatos</surname><given-names>L.</given-names></name><name><surname>Polonis</surname><given-names>V.R.</given-names></name><name><surname>Koutsoukos</surname><given-names>M.</given-names></name><name><surname>Voss</surname><given-names>G.</given-names></name><name><surname>Goepfert</surname><given-names>P.</given-names></name><name><surname>Gilbert</surname><given-names>P.</given-names></name><name><surname>Greene</surname><given-names>K.M.</given-names></name></person-group><article-title>Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies</article-title><source>J. Virol.</source><volume>79</volume><year>2005</year><fpage>10108</fpage><lpage>10125</lpage><pub-id pub-id-type="pmid">16051804</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>H.X.</given-names></name><name><surname>Bonsignori</surname><given-names>M.</given-names></name><name><surname>Alam</surname><given-names>S.M.</given-names></name><name><surname>McLellan</surname><given-names>J.S.</given-names></name><name><surname>Tomaras</surname><given-names>G.D.</given-names></name><name><surname>Moody</surname><given-names>M.A.</given-names></name><name><surname>Kozink</surname><given-names>D.M.</given-names></name><name><surname>Hwang</surname><given-names>K.K.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Tsao</surname><given-names>C.Y.</given-names></name></person-group><article-title>Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2</article-title><source>Immunity</source><volume>38</volume><year>2013</year><fpage>176</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">23313589</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>R.M.</given-names></name><name><surname>Wong</surname><given-names>P.</given-names></name><name><surname>Tran</surname><given-names>L.</given-names></name><name><surname>O&#x02019;Dell</surname><given-names>S.</given-names></name><name><surname>Nason</surname><given-names>M.C.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Mascola</surname><given-names>J.R.</given-names></name></person-group><article-title>HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies</article-title><source>J.&#x000a0;Virol.</source><volume>89</volume><year>2015</year><fpage>4201</fpage><lpage>4213</lpage><pub-id pub-id-type="pmid">25631091</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>McLellan</surname><given-names>J.S.</given-names></name><name><surname>Pancera</surname><given-names>M.</given-names></name><name><surname>Carrico</surname><given-names>C.</given-names></name><name><surname>Gorman</surname><given-names>J.</given-names></name><name><surname>Julien</surname><given-names>J.P.</given-names></name><name><surname>Khayat</surname><given-names>R.</given-names></name><name><surname>Louder</surname><given-names>R.</given-names></name><name><surname>Pejchal</surname><given-names>R.</given-names></name><name><surname>Sastry</surname><given-names>M.</given-names></name><name><surname>Dai</surname><given-names>K.</given-names></name></person-group><article-title>Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9</article-title><source>Nature</source><volume>480</volume><year>2011</year><fpage>336</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">22113616</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="other" id="sref57"><person-group person-group-type="author"><name><surname>McLeod</surname><given-names>A.I.</given-names></name></person-group><article-title>Kendall: Kendall Rank Correlation and Mann-Kendall Trend Test</article-title><ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/Kendall/Kendall.pdf" id="intref0175">https://cran.r-project.org/web/packages/Kendall/Kendall.pdf</ext-link><year>2011</year></element-citation></ref><ref id="bib58"><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Mouquet</surname><given-names>H.</given-names></name><name><surname>Scharf</surname><given-names>L.</given-names></name><name><surname>Euler</surname><given-names>Z.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Eden</surname><given-names>C.</given-names></name><name><surname>Scheid</surname><given-names>J.F.</given-names></name><name><surname>Halper-Stromberg</surname><given-names>A.</given-names></name><name><surname>Gnanapragasam</surname><given-names>P.N.</given-names></name><name><surname>Spencer</surname><given-names>D.I.</given-names></name><name><surname>Seaman</surname><given-names>M.S.</given-names></name></person-group><article-title>Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>109</volume><year>2012</year><fpage>E3268</fpage><lpage>E3277</lpage><pub-id pub-id-type="pmid">23115339</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>J.D.</given-names></name><name><surname>Brunel</surname><given-names>F.M.</given-names></name><name><surname>Jensen</surname><given-names>R.</given-names></name><name><surname>Crooks</surname><given-names>E.T.</given-names></name><name><surname>Cardoso</surname><given-names>R.M.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Hessell</surname><given-names>A.</given-names></name><name><surname>Wilson</surname><given-names>I.A.</given-names></name><name><surname>Binley</surname><given-names>J.M.</given-names></name><name><surname>Dawson</surname><given-names>P.E.</given-names></name></person-group><article-title>An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10</article-title><source>J.&#x000a0;Virol.</source><volume>81</volume><year>2007</year><fpage>4033</fpage><lpage>4043</lpage><pub-id pub-id-type="pmid">17287272</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Nickle</surname><given-names>D.C.</given-names></name><name><surname>Heath</surname><given-names>L.</given-names></name><name><surname>Jensen</surname><given-names>M.A.</given-names></name><name><surname>Gilbert</surname><given-names>P.B.</given-names></name><name><surname>Mullins</surname><given-names>J.I.</given-names></name><name><surname>Kosakovsky Pond</surname><given-names>S.L.</given-names></name></person-group><article-title>HIV-specific probabilistic models of protein evolution</article-title><source>PLoS One</source><volume>2</volume><year>2007</year><fpage>e503</fpage><pub-id pub-id-type="pmid">17551583</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Nkolola</surname><given-names>J.P.</given-names></name><name><surname>Bricault</surname><given-names>C.A.</given-names></name><name><surname>Cheung</surname><given-names>A.</given-names></name><name><surname>Shields</surname><given-names>J.</given-names></name><name><surname>Perry</surname><given-names>J.</given-names></name><name><surname>Kovacs</surname><given-names>J.M.</given-names></name><name><surname>Giorgi</surname><given-names>E.</given-names></name><name><surname>van Winsen</surname><given-names>M.</given-names></name><name><surname>Apetri</surname><given-names>A.</given-names></name><name><surname>Brinkman-van der Linden</surname><given-names>E.C.M.</given-names></name></person-group><article-title>Characterization and immunogenicity of a novel mosaic M HIV-1 gp140 trimer</article-title><source>J.&#x000a0;Virol.</source><volume>88</volume><year>2014</year><fpage>9538</fpage><lpage>9552</lpage><pub-id pub-id-type="pmid">24965452</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Nkolola</surname><given-names>J.P.</given-names></name><name><surname>Cheung</surname><given-names>A.</given-names></name><name><surname>Perry</surname><given-names>J.R.</given-names></name><name><surname>Carter</surname><given-names>D.</given-names></name><name><surname>Reed</surname><given-names>S.</given-names></name><name><surname>Schuitemaker</surname><given-names>H.</given-names></name><name><surname>Pau</surname><given-names>M.G.</given-names></name><name><surname>Seaman</surname><given-names>M.S.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Barouch</surname><given-names>D.H.</given-names></name></person-group><article-title>Comparison of multiple adjuvants on the stability and immunogenicity of a clade C HIV-1 gp140 trimer</article-title><source>Vaccine</source><volume>32</volume><year>2014</year><fpage>2109</fpage><lpage>2116</lpage><pub-id pub-id-type="pmid">24556505</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Nkolola</surname><given-names>J.P.</given-names></name><name><surname>Peng</surname><given-names>H.</given-names></name><name><surname>Settembre</surname><given-names>E.C.</given-names></name><name><surname>Freeman</surname><given-names>M.</given-names></name><name><surname>Grandpre</surname><given-names>L.E.</given-names></name><name><surname>Devoy</surname><given-names>C.</given-names></name><name><surname>Lynch</surname><given-names>D.M.</given-names></name><name><surname>La Porte</surname><given-names>A.</given-names></name><name><surname>Simmons</surname><given-names>N.L.</given-names></name><name><surname>Bradley</surname><given-names>R.</given-names></name></person-group><article-title>Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs</article-title><source>J.&#x000a0;Virol.</source><volume>84</volume><year>2010</year><fpage>3270</fpage><lpage>3279</lpage><pub-id pub-id-type="pmid">20053749</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal" id="sref97"><person-group person-group-type="author"><name><surname>Ofek</surname><given-names>G.</given-names></name><name><surname>Tang</surname><given-names>M.</given-names></name><name><surname>Sambor</surname><given-names>A.</given-names></name><name><surname>Katinger</surname><given-names>H.</given-names></name><name><surname>Mascola</surname><given-names>J.R.</given-names></name><name><surname>Wyatt</surname><given-names>R.</given-names></name><name><surname>Kwong</surname><given-names>P.D.</given-names></name></person-group><article-title>Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope</article-title><source>J. Virol.</source><volume>78</volume><year>2004</year><fpage>10724</fpage><lpage>10737</lpage><pub-id pub-id-type="pmid">15367639</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Paradis</surname><given-names>E.</given-names></name><name><surname>Claude</surname><given-names>J.</given-names></name><name><surname>Strimmer</surname><given-names>K.</given-names></name></person-group><article-title>APE: analyses of phylogenetics and evolution in R language</article-title><source>Bioinformatics</source><volume>20</volume><year>2004</year><fpage>289</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">14734327</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Parrish</surname><given-names>N.F.</given-names></name><name><surname>Gao</surname><given-names>F.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Giorgi</surname><given-names>E.E.</given-names></name><name><surname>Barbian</surname><given-names>H.J.</given-names></name><name><surname>Parrish</surname><given-names>E.H.</given-names></name><name><surname>Zajic</surname><given-names>L.</given-names></name><name><surname>Iyer</surname><given-names>S.S.</given-names></name><name><surname>Decker</surname><given-names>J.M.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name></person-group><article-title>Phenotypic properties of transmitted founder HIV-1</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>110</volume><year>2013</year><fpage>6626</fpage><lpage>6633</lpage><pub-id pub-id-type="pmid">23542380</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Pauthner</surname><given-names>M.</given-names></name><name><surname>Havenar-Daughton</surname><given-names>C.</given-names></name><name><surname>Sok</surname><given-names>D.</given-names></name><name><surname>Nkolola</surname><given-names>J.P.</given-names></name><name><surname>Bastidas</surname><given-names>R.</given-names></name><name><surname>Boopathy</surname><given-names>A.V.</given-names></name><name><surname>Carnathan</surname><given-names>D.G.</given-names></name><name><surname>Chandrashekar</surname><given-names>A.</given-names></name><name><surname>Cirelli</surname><given-names>K.M.</given-names></name><name><surname>Cottrell</surname><given-names>C.A.</given-names></name></person-group><article-title>Elicitation of robust tier 2 neutralizing antibody responses in nonhuman primates by HIV envelope trimer immunization using optimized approaches</article-title><source>Immunity</source><volume>46</volume><year>2017</year><fpage>1073</fpage><lpage>1088.e6</lpage><pub-id pub-id-type="pmid">28636956</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Pedregosa</surname><given-names>F.</given-names></name><name><surname>Varoquaux</surname><given-names>G.</given-names></name><name><surname>Gramfort</surname><given-names>A.</given-names></name><name><surname>Michel</surname><given-names>V.</given-names></name><name><surname>Thirion</surname><given-names>B.</given-names></name><name><surname>Grisel</surname><given-names>O.</given-names></name><name><surname>Blondel</surname><given-names>M.</given-names></name><name><surname>Prettenhofer</surname><given-names>P.</given-names></name><name><surname>Weiss</surname><given-names>R.</given-names></name><name><surname>Dubourg</surname><given-names>V.</given-names></name></person-group><article-title>Scikit-learn: machine learning in Python</article-title><source>J.&#x000a0;Mach. Learn. Res.</source><volume>12</volume><year>2011</year><fpage>2825</fpage><lpage>2830</lpage></element-citation></ref><ref id="bib68"><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Pejchal</surname><given-names>R.</given-names></name><name><surname>Doores</surname><given-names>K.J.</given-names></name><name><surname>Walker</surname><given-names>L.M.</given-names></name><name><surname>Khayat</surname><given-names>R.</given-names></name><name><surname>Huang</surname><given-names>P.-S.</given-names></name><name><surname>Wang</surname><given-names>S.-K.</given-names></name><name><surname>Stanfield</surname><given-names>R.L.</given-names></name><name><surname>Julien</surname><given-names>J.-P.</given-names></name><name><surname>Ramos</surname><given-names>A.</given-names></name><name><surname>Crispin</surname><given-names>M.</given-names></name></person-group><article-title>A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield</article-title><source>Science</source><volume>334</volume><year>2011</year><fpage>1097</fpage><lpage>1103</lpage><pub-id pub-id-type="pmid">21998254</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>H.</given-names></name><name><surname>Long</surname><given-names>F.</given-names></name><name><surname>Ding</surname><given-names>C.</given-names></name></person-group><article-title>Feature selection based on mutual information: criteria of max-dependency, max-relevance, and min-redundancy</article-title><source>IEEE Trans. Pattern Anal. Mach. Intell.</source><volume>27</volume><year>2005</year><fpage>1226</fpage><lpage>1238</lpage><pub-id pub-id-type="pmid">16119262</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Rademeyer</surname><given-names>C.</given-names></name><name><surname>Korber</surname><given-names>B.</given-names></name><name><surname>Seaman</surname><given-names>M.S.</given-names></name><name><surname>Giorgi</surname><given-names>E.E.</given-names></name><name><surname>Thebus</surname><given-names>R.</given-names></name><name><surname>Robles</surname><given-names>A.</given-names></name><name><surname>Sheward</surname><given-names>D.J.</given-names></name><name><surname>Wagh</surname><given-names>K.</given-names></name><name><surname>Garrity</surname><given-names>J.</given-names></name><name><surname>Carey</surname><given-names>B.R.</given-names></name></person-group><article-title>Features of recently transmitted HIV-1 Clade C viruses that impact antibody recognition: implications for active and passive immunization</article-title><source>PLoS Pathog.</source><volume>12</volume><year>2016</year><fpage>e1005742</fpage><pub-id pub-id-type="pmid">27434311</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal" id="sref71"><person-group person-group-type="author"><name><surname>Rudicell</surname><given-names>R.S.</given-names></name><name><surname>Kwon</surname><given-names>Y.D.</given-names></name><name><surname>Ko</surname><given-names>S.-Y.</given-names></name><name><surname>Pegu</surname><given-names>A.</given-names></name><name><surname>Louder</surname><given-names>M.K.</given-names></name><name><surname>Georgiev</surname><given-names>I.S.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Boyington</surname><given-names>J.C.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name></person-group><article-title>Enhanced potency of a broadly neutralizing HIV-1 antibody in&#x000a0;vitro improves protection against lentiviral infection in&#x000a0;vivo</article-title><source>J.&#x000a0;Virol.</source><volume>88</volume><year>2014</year><fpage>12669</fpage><lpage>12682</lpage><pub-id pub-id-type="pmid">25142607</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal" id="sref72"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>R.W.</given-names></name><name><surname>Derking</surname><given-names>R.</given-names></name><name><surname>Cupo</surname><given-names>A.</given-names></name><name><surname>Julien</surname><given-names>J.P.</given-names></name><name><surname>Yasmeen</surname><given-names>A.</given-names></name><name><surname>de Val</surname><given-names>N.</given-names></name><name><surname>Kim</surname><given-names>H.J.</given-names></name><name><surname>Blattner</surname><given-names>C.</given-names></name><name><surname>de la Pena</surname><given-names>A.T.</given-names></name><name><surname>Korzun</surname><given-names>J.</given-names></name></person-group><article-title>A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP. 664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies,</article-title><source>PLoS Pathog.</source><volume>9</volume><year>2013</year><fpage>e1003618</fpage><pub-id pub-id-type="pmid">24068931</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal" id="sref73"><person-group person-group-type="author"><name><surname>Sanders</surname><given-names>R.W.</given-names></name><name><surname>van Gils</surname><given-names>M.J.</given-names></name><name><surname>Derking</surname><given-names>R.</given-names></name><name><surname>Sok</surname><given-names>D.</given-names></name><name><surname>Ketas</surname><given-names>T.J.</given-names></name><name><surname>Burger</surname><given-names>J.A.</given-names></name><name><surname>Ozorowski</surname><given-names>G.</given-names></name><name><surname>Cupo</surname><given-names>A.</given-names></name><name><surname>Simonich</surname><given-names>C.</given-names></name><name><surname>Goo</surname><given-names>L.</given-names></name></person-group><article-title>HIV-1 vaccines. HIV-1 neutralizing antibodies induced by native-like envelope trimers</article-title><source>Science</source><volume>349</volume><year>2015</year><fpage>aac4223</fpage><pub-id pub-id-type="pmid">26089353</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal" id="sref74"><person-group person-group-type="author"><name><surname>Sarzotti-Kelsoe</surname><given-names>M.</given-names></name><name><surname>Bailer</surname><given-names>R.T.</given-names></name><name><surname>Turk</surname><given-names>E.</given-names></name><name><surname>Lin</surname><given-names>C.L.</given-names></name><name><surname>Bilska</surname><given-names>M.</given-names></name><name><surname>Greene</surname><given-names>K.M.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Todd</surname><given-names>C.A.</given-names></name><name><surname>Ozaki</surname><given-names>D.A.</given-names></name><name><surname>Seaman</surname><given-names>M.S.</given-names></name></person-group><article-title>Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1</article-title><source>J.&#x000a0;Immunol. Methods</source><volume>409</volume><year>2014</year><fpage>131</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">24291345</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal" id="sref75"><person-group person-group-type="author"><name><surname>Saunders</surname><given-names>K.O.</given-names></name><name><surname>Verkoczy</surname><given-names>L.K.</given-names></name><name><surname>Jiang</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Parks</surname><given-names>R.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Housman</surname><given-names>M.</given-names></name><name><surname>Bouton-Verville</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>X.</given-names></name><name><surname>Trama</surname><given-names>A.M.</given-names></name></person-group><article-title>Vaccine induction of heterologous Tier 2 HIV-1 neutralizing antibodies in animal models</article-title><source>Cell Rep.</source><volume>21</volume><year>2017</year><fpage>3681</fpage><lpage>3690</lpage><pub-id pub-id-type="pmid">29281818</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal" id="sref98"><person-group person-group-type="author"><name><surname>Scheid</surname><given-names>J.F.</given-names></name><name><surname>Horwitz</surname><given-names>J.A.</given-names></name><name><surname>Bar-On</surname><given-names>Y.</given-names></name><name><surname>Kreider</surname><given-names>E.F.</given-names></name><name><surname>Lu</surname><given-names>C.L.</given-names></name><name><surname>Lorenzi</surname><given-names>J.C.</given-names></name><name><surname>Feldmann</surname><given-names>A.</given-names></name><name><surname>Braunschweig</surname><given-names>M.</given-names></name><name><surname>Nogueira</surname><given-names>L.</given-names></name><name><surname>Oliveira</surname><given-names>T.</given-names></name></person-group><article-title>HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption</article-title><source>Nature</source><volume>535</volume><year>2016</year><fpage>556</fpage><lpage>560</lpage><pub-id pub-id-type="pmid">27338952</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal" id="sref76"><person-group person-group-type="author"><name><surname>Scheid</surname><given-names>J.F.</given-names></name><name><surname>Mouquet</surname><given-names>H.</given-names></name><name><surname>Ueberheide</surname><given-names>B.</given-names></name><name><surname>Diskin</surname><given-names>R.</given-names></name><name><surname>Klein</surname><given-names>F.</given-names></name><name><surname>Oliveira</surname><given-names>T.Y.K.</given-names></name><name><surname>Pietzsch</surname><given-names>J.</given-names></name><name><surname>Fenyo</surname><given-names>D.</given-names></name><name><surname>Abadir</surname><given-names>A.</given-names></name><name><surname>Velinzon</surname><given-names>K.</given-names></name></person-group><article-title>Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding</article-title><source>Science</source><volume>333</volume><year>2011</year><fpage>1633</fpage><lpage>1637</lpage><pub-id pub-id-type="pmid">21764753</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal" id="sref77"><person-group person-group-type="author"><name><surname>Sok</surname><given-names>D.</given-names></name><name><surname>Pauthner</surname><given-names>M.</given-names></name><name><surname>Briney</surname><given-names>B.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Saye-Francisco</surname><given-names>K.L.</given-names></name><name><surname>Hsueh</surname><given-names>J.</given-names></name><name><surname>Ramos</surname><given-names>A.</given-names></name><name><surname>Le</surname><given-names>K.M.</given-names></name><name><surname>Jones</surname><given-names>M.</given-names></name><name><surname>Jardine</surname><given-names>J.G.</given-names></name></person-group><article-title>A prominent site of antibody vulnerability on HIV envelope incorporates a motif associated with CCR5 binding and its camouflaging glycans</article-title><source>Immunity</source><volume>45</volume><year>2016</year><fpage>31</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">27438765</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal" id="sref78"><person-group person-group-type="author"><name><surname>Sok</surname><given-names>D.</given-names></name><name><surname>van Gils</surname><given-names>M.J.</given-names></name><name><surname>Pauthner</surname><given-names>M.</given-names></name><name><surname>Julien</surname><given-names>J.P.</given-names></name><name><surname>Saye-Francisco</surname><given-names>K.L.</given-names></name><name><surname>Hsueh</surname><given-names>J.</given-names></name><name><surname>Briney</surname><given-names>B.</given-names></name><name><surname>Lee</surname><given-names>J.H.</given-names></name><name><surname>Le</surname><given-names>K.M.</given-names></name><name><surname>Lee</surname><given-names>P.S.</given-names></name></person-group><article-title>Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>111</volume><year>2014</year><fpage>17624</fpage><lpage>17629</lpage><pub-id pub-id-type="pmid">25422458</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal" id="sref79"><person-group person-group-type="author"><name><surname>Steichen</surname><given-names>J.M.</given-names></name><name><surname>Kulp</surname><given-names>D.W.</given-names></name><name><surname>Tokatlian</surname><given-names>T.</given-names></name><name><surname>Escolano</surname><given-names>A.</given-names></name><name><surname>Dosenovic</surname><given-names>P.</given-names></name><name><surname>Stanfield</surname><given-names>R.L.</given-names></name><name><surname>McCoy</surname><given-names>L.E.</given-names></name><name><surname>Ozorowski</surname><given-names>G.</given-names></name><name><surname>Hu</surname><given-names>X.</given-names></name><name><surname>Kalyuzhniy</surname><given-names>O.</given-names></name></person-group><article-title>HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies</article-title><source>Immunity</source><volume>45</volume><year>2016</year><fpage>483</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">27617678</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal" id="sref80"><person-group person-group-type="author"><name><surname>Stephenson</surname><given-names>K.E.</given-names></name><name><surname>Neubauer</surname><given-names>G.H.</given-names></name><name><surname>Reimer</surname><given-names>U.</given-names></name><name><surname>Pawlowski</surname><given-names>N.</given-names></name><name><surname>Knaute</surname><given-names>T.</given-names></name><name><surname>Zerweck</surname><given-names>J.</given-names></name><name><surname>Korber</surname><given-names>B.T.</given-names></name><name><surname>Barouch</surname><given-names>D.H.</given-names></name></person-group><article-title>Quantification of the epitope diversity of HIV-1-specific binding antibodies by peptide microarrays for global HIV-1 vaccine development</article-title><source>J.&#x000a0;Immunol. Methods</source><volume>416</volume><year>2015</year><fpage>105</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">25445329</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal" id="sref99"><person-group person-group-type="author"><name><surname>Stewart-Jones</surname><given-names>G.B.</given-names></name><name><surname>Soto</surname><given-names>C.</given-names></name><name><surname>Lemmin</surname><given-names>T.</given-names></name><name><surname>Chuang</surname><given-names>G.Y.</given-names></name><name><surname>Druz</surname><given-names>A.</given-names></name><name><surname>Kong</surname><given-names>R.</given-names></name><name><surname>Thomas</surname><given-names>P.V.</given-names></name><name><surname>Wagh</surname><given-names>K.</given-names></name><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>Behrens</surname><given-names>A.J.</given-names></name></person-group><article-title>Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G</article-title><source>Cell</source><volume>165</volume><year>2016</year><fpage>813</fpage><lpage>826</lpage><pub-id pub-id-type="pmid">27114034</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal" id="sref81"><person-group person-group-type="author"><name><surname>Storey</surname><given-names>J.D.</given-names></name><name><surname>Tibshirani</surname><given-names>R.</given-names></name></person-group><article-title>Statistical significance for genomewide studies</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>100</volume><year>2003</year><fpage>9440</fpage><lpage>9445</lpage><pub-id pub-id-type="pmid">12883005</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal" id="sref82"><person-group person-group-type="author"><name><surname>Trkola</surname><given-names>A.</given-names></name><name><surname>Purtscher</surname><given-names>M.</given-names></name><name><surname>Muster</surname><given-names>T.</given-names></name><name><surname>Ballaun</surname><given-names>C.</given-names></name><name><surname>Buchacher</surname><given-names>A.</given-names></name><name><surname>Sullivan</surname><given-names>N.</given-names></name><name><surname>Srinivasan</surname><given-names>K.</given-names></name><name><surname>Sodroski</surname><given-names>J.</given-names></name><name><surname>Moore</surname><given-names>J.P.</given-names></name><name><surname>Katinger</surname><given-names>H.</given-names></name></person-group><article-title>Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1</article-title><source>J.&#x000a0;Virol.</source><volume>70</volume><year>1996</year><fpage>1100</fpage><lpage>1108</lpage><pub-id pub-id-type="pmid">8551569</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal" id="sref83"><person-group person-group-type="author"><name><surname>Wagh</surname><given-names>K.</given-names></name><name><surname>Bhattacharya</surname><given-names>T.</given-names></name><name><surname>Williamson</surname><given-names>C.</given-names></name><name><surname>Robles</surname><given-names>A.</given-names></name><name><surname>Bayne</surname><given-names>M.</given-names></name><name><surname>Garrity</surname><given-names>J.</given-names></name><name><surname>Rist</surname><given-names>M.</given-names></name><name><surname>Rademeyer</surname><given-names>C.</given-names></name><name><surname>Yoon</surname><given-names>H.</given-names></name><name><surname>Lapedes</surname><given-names>A.</given-names></name></person-group><article-title>Optimal combinations of broadly neutralizing antibodies for prevention and treatment of HIV-1 Clade C infection</article-title><source>PLoS Pathog.</source><volume>12</volume><year>2016</year><fpage>e1005520</fpage><pub-id pub-id-type="pmid">27028935</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal" id="sref84"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>L.M.</given-names></name><name><surname>Huber</surname><given-names>M.</given-names></name><name><surname>Doores</surname><given-names>K.J.</given-names></name><name><surname>Falkowska</surname><given-names>E.</given-names></name><name><surname>Pejchal</surname><given-names>R.</given-names></name><name><surname>Julien</surname><given-names>J.P.</given-names></name><name><surname>Wang</surname><given-names>S.K.</given-names></name><name><surname>Ramos</surname><given-names>A.</given-names></name><name><surname>Chan-Hui</surname><given-names>P.Y.</given-names></name><name><surname>Moyle</surname><given-names>M.</given-names></name></person-group><article-title>Broad neutralization coverage of HIV by multiple highly potent antibodies</article-title><source>Nature</source><volume>477</volume><year>2011</year><fpage>466</fpage><lpage>470</lpage><pub-id pub-id-type="pmid">21849977</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal" id="sref85"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>L.M.</given-names></name><name><surname>Phogat</surname><given-names>S.K.</given-names></name><name><surname>Chan-Hui</surname><given-names>P.Y.</given-names></name><name><surname>Wagner</surname><given-names>D.</given-names></name><name><surname>Phung</surname><given-names>P.</given-names></name><name><surname>Goss</surname><given-names>J.L.</given-names></name><name><surname>Wrin</surname><given-names>T.</given-names></name><name><surname>Simek</surname><given-names>M.D.</given-names></name><name><surname>Fling</surname><given-names>S.</given-names></name><name><surname>Mitcham</surname><given-names>J.L.</given-names></name></person-group><article-title>Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target</article-title><source>Science</source><volume>326</volume><year>2009</year><fpage>285</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">19729618</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal" id="sref86"><person-group person-group-type="author"><name><surname>West</surname><given-names>A.P.</given-names><suffix>Jr.</suffix></name><name><surname>Scharf</surname><given-names>L.</given-names></name><name><surname>Horwitz</surname><given-names>J.</given-names></name><name><surname>Klein</surname><given-names>F.</given-names></name><name><surname>Nussenzweig</surname><given-names>M.C.</given-names></name><name><surname>Bjorkman</surname><given-names>P.J.</given-names></name></person-group><article-title>Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>110</volume><year>2013</year><fpage>10598</fpage><lpage>10603</lpage><pub-id pub-id-type="pmid">23754383</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal" id="sref87"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>L.D.</given-names></name><name><surname>Ofek</surname><given-names>G.</given-names></name><name><surname>Sch&#x000e4;tzle</surname><given-names>S.</given-names></name><name><surname>McDaniel</surname><given-names>J.R.</given-names></name><name><surname>Lu</surname><given-names>X.</given-names></name><name><surname>Nicely</surname><given-names>N.I.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Lougheed</surname><given-names>C.S.</given-names></name><name><surname>Bradley</surname><given-names>T.</given-names></name><name><surname>Louder</surname><given-names>M.K.</given-names></name></person-group><article-title>Potent and broad HIV neutralizing antibodies in memory B cells and plasma</article-title><source>Sci. Immunol.</source><volume>2</volume><year>2017</year></element-citation></ref><ref id="bib88"><element-citation publication-type="journal" id="sref88"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Z.Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Hogerkorp</surname><given-names>C.M.</given-names></name><name><surname>Schief</surname><given-names>W.R.</given-names></name><name><surname>Seaman</surname><given-names>M.S.</given-names></name><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>Schmidt</surname><given-names>S.D.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name></person-group><article-title>Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1</article-title><source>Science</source><volume>329</volume><year>2010</year><fpage>856</fpage><lpage>861</lpage><pub-id pub-id-type="pmid">20616233</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal" id="sref89"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Schramm</surname><given-names>C.A.</given-names></name><name><surname>Joyce</surname><given-names>M.G.</given-names></name><name><surname>Kwon</surname><given-names>Y.D.</given-names></name><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>Sheng</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>O'Dell</surname><given-names>S.</given-names></name><name><surname>McKee</surname><given-names>K.</given-names></name></person-group><article-title>Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection</article-title><source>Cell</source><volume>161</volume><year>2015</year><fpage>470</fpage><lpage>485</lpage><pub-id pub-id-type="pmid">25865483</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal" id="sref90"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Georgiev</surname><given-names>I.</given-names></name><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Longo</surname><given-names>N.S.</given-names></name><name><surname>Louder</surname><given-names>M.</given-names></name><name><surname>McKee</surname><given-names>K.</given-names></name></person-group><article-title>Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing</article-title><source>Science</source><volume>333</volume><year>2011</year><fpage>1593</fpage><lpage>1602</lpage><pub-id pub-id-type="pmid">21835983</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal" id="sref91"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>H.</given-names></name><name><surname>Macke</surname><given-names>J.</given-names></name><name><surname>West</surname><given-names>A.P.</given-names><suffix>Jr.</suffix></name><name><surname>Foley</surname><given-names>B.</given-names></name><name><surname>Bjorkman</surname><given-names>P.J.</given-names></name><name><surname>Korber</surname><given-names>B.</given-names></name><name><surname>Yusim</surname><given-names>K.</given-names></name></person-group><article-title>CATNAP: a tool to compile, analyze and tally neutralizing antibody panels</article-title><source>Nucleic Acids Res.</source><volume>43</volume><year>2015</year><fpage>W213</fpage><lpage>W219</lpage><pub-id pub-id-type="pmid">26044712</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal" id="sref100"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Dey</surname><given-names>B.</given-names></name><name><surname>Hessell</surname><given-names>A.J.</given-names></name><name><surname>Van Ryk</surname><given-names>D.</given-names></name><name><surname>Xiang</surname><given-names>S.H.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>M.Y.</given-names></name><name><surname>Zwick</surname><given-names>M.B.</given-names></name><name><surname>Arthos</surname><given-names>J.</given-names></name></person-group><article-title>Structural definition of a conserved neutralization epitope on HIV-1 gp120</article-title><source>Nature</source><volume>445</volume><year>2007</year><fpage>732</fpage><lpage>737</lpage><pub-id pub-id-type="pmid">17301785</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal" id="sref92"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>Georgiev</surname><given-names>I.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>Z.Y.</given-names></name><name><surname>Dai</surname><given-names>K.</given-names></name><name><surname>Finzi</surname><given-names>A.</given-names></name><name><surname>Kwon</surname><given-names>Y.D.</given-names></name><name><surname>Scheid</surname><given-names>J.F.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name></person-group><article-title>Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01</article-title><source>Science</source><volume>329</volume><year>2010</year><fpage>811</fpage><lpage>817</lpage><pub-id pub-id-type="pmid">20616231</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal" id="sref93"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>Lynch</surname><given-names>R.M.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Acharya</surname><given-names>P.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Doria-Rose</surname><given-names>N.A.</given-names></name><name><surname>Joyce</surname><given-names>M.G.</given-names></name><name><surname>Lingwood</surname><given-names>D.</given-names></name><name><surname>Soto</surname><given-names>C.</given-names></name><name><surname>Bailer</surname><given-names>R.T.</given-names></name></person-group><article-title>Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 Supersite in 14 donors</article-title><source>Cell</source><volume>161</volume><year>2015</year><fpage>1280</fpage><lpage>1292</lpage><pub-id pub-id-type="pmid">26004070</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal" id="sref94"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>T.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Moquin</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Acharya</surname><given-names>P.</given-names></name><name><surname>Georgiev</surname><given-names>I.S.</given-names></name><name><surname>Altae-Tran</surname><given-names>H.R.</given-names></name><name><surname>Chuang</surname><given-names>G.Y.</given-names></name><name><surname>Joyce</surname><given-names>M.G.</given-names></name></person-group><article-title>Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies</article-title><source>Immunity</source><volume>39</volume><year>2013</year><fpage>245</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">23911655</pub-id></element-citation></ref></ref-list><sec id="app2" sec-type="supplementary-material"><title>Supplemental Information</title><p id="p0395"><supplementary-material content-type="local-data" id="mmc1"><caption><title>Document S1. Figures S1&#x02013;S7 and Tables S1, S2, S4, S5, and S7</title></caption><media xlink:href="mmc1.pdf"/></supplementary-material><supplementary-material content-type="local-data" id="mmc2"><caption><title>Table S3. All Signature Tables for All Antibodies and Datasets, Related to Figures 3 and 4</title><p>A-D. Summary tables organized by site, amino acids, and antibodies, and providing an overview of all signature sites found for a given antibody class, across all 4 datasets.</p><p>Separate tabs are provided for each bNAb class studied (tabs A-D). Sites within hypervariable regions are excluded. The antibodies included in each of the four primary datasets are listed at the top. Sites are included as a signature if at least one antibody in one dataset had a phylogenetically corrected signature site with a q-value of&#x000a0;&#x0003c; 0.2 (<xref rid="mmc2" ref-type="supplementary-material">Table S3</xref> tabs E-H) or if the signature site was in a contact residue. If either of these criteria was met, the site was deemed of interest, and all simple (without a phylogenetic correction) Fisher&#x02019;s exact associations with a q-value&#x000a0;&#x0003c; 0.2 were then included and tracked for that site. Complete details of statistical support for each signature are included in <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref> tabs E-H (phylogenetic corrected signatures only, organized by antibody) and S3 tabs I-L (all simple associations for sites of interest, organized by site). Antibodies with significant associations after a phylogenetic correction (from <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref>E-H) are bold. The positions are based on HXB2 numbering. If the site is known to be in a contact site for an antibody in the class, based on structural studies, the position number is colored and bold. Amino acids significantly associated with bNAb resistance are colored red, those that are associated with sensitivity are blue. Glycosylation site patterns were tracked, and a PNGS motif is noted as &#x0201c;NxST&#x0201d;. Note that lack of an association in a particular dataset does not mean that the association in another is not valid for a given antibody, it may simply mean that a given dataset did not have enough power to resolve the association statistically. If a particular site was associated with bNAbs sensitivity/resistance in multiple datasets, for more than one bNAb in a class, or was located in a known contact residue, it was deemed likely to be robust as it was supported by several lines of evidence (HXB2 position numbers of such sites are highlighted in bold). These more robust associations were used as a basis for the signature profiles in <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref> in the main body of the text and for structural mapping. Contradictory signatures, associated with sensitivity to some antibodies in a class, but resistance to others, are highlighted in tan. Tabs:</p><p>A.V3 bNAb signature summary. Contact residues are indicated in blue in the Position column.</p><p>B. V2 bNAb signature summary. Contact residues are indicated in green in the Position column.</p><p>C. CD4bs bNAb signature summary. The HXB2 positions of contact residues as described in the legend to <xref rid="mmc1" ref-type="supplementary-material">Table S4</xref>C are indicated by lavender text. Most CD4bs bNAbs are VH1-2 or VH-46 using and are noted in black. The sites that were used for the illustration in the main paper in <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref> focus on VH1-2 or VH-46 usage CD4bs bNAb signatures. Antibody names in red include CDRH3 dominated antibodies (<xref rid="bib93" ref-type="bibr">Zhou et&#x000a0;al., 2015</xref>) CH103, HJ16, VRC13, VRC16, and IgG1b12, plus two VH1-2 antibodies, VRC03 and VRC06, that tended to track with CDRH3 bNAbs in terms of signature associations. These antibodies generally have less breadth and often have contradictory signatures relative to most VH1-2 or VH-46 using CD4bs bNAbs.</p><p>D. <bold>D.</bold> MPER bNAb signature summary. Contact residues are indicated in the Position in dark brown for 2F5, light brown for 4E10/10E8/DH511.</p><p>E-H. Phylogenetically corrected signatures, organized by antibody<bold>.</bold> These tables list the statistical support for all phylogenetically corrected amino acid signatures with q-values &#x0003c;0.2 for each antibody studied, organized by antibody class and antibody, providing details regarding signatures statistics. Separate tabs are provided for each bNAb class studied (S3 E-H). The phylogenetic correction compares to the neutralization phenotype the amino acids in sites that are unchanging to those that change between a taxon and its most recent ancestral node as estimated using a maximum likelihood tree. The column headings are as follows. The &#x0201c;<italic>Table</italic>&#x0201d; columns are T2 and T3, for Table 2 and 3. These tables are phylogenetically corrected signatures. A detailed example of how to read each kind of table is provided in each spreadsheet. If the signature analysis was testing for N-linked glycosylation sites rather than simple amino acids, it is indicated as a &#x0201c;glycan&#x0201d; table, e<italic>.</italic>g<italic>.</italic> T2glycan. The <italic>Dataset</italic> is either: the first (1) or second (2) completely independent M group datasets, the C clade dataset (3), or the larger M group data (4), shown in <xref rid="mmc1" ref-type="supplementary-material">Figure&#x000a0;S1</xref>. The <italic>cutoff</italic> is the cutoff used for the input phenotype that gave the highest degree of statistical support for a particular signature. <italic>PosNeg</italic> means the data was broken down between positive, i.e. a detected IC<sub>50</sub>, and negative, with IC<sub>50</sub> above the threshold of detection. Data was also broken down by above or below the median titer, and upper and lower quartiles. The <italic>HXB2 pos</italic> is the position in the alignment based on HXB2 numbering. The <italic>test AA</italic> is the amino acid that was being evaluated in the position; only those with a q-value &#x0003c;0.2 are included. Also, we excluded a small number of cases when phylogenetic association were not also supported by a simple uncorrected association. If <italic>blue</italic>, its presence was associated with enhanced sensitivity, if <italic>red</italic>, with resistance. NxST is an abbreviation to refer to an intact N-linked glycosylation site motif. <italic>Antibody</italic> is the name of the bNAb. <italic>P-value</italic>, <italic>q-value</italic> and <italic>Odds Ratio</italic> are all summary statistics, that are based on the 2x2 contingency tables that are outlined as r1c1, r1c2, r2c1, r2c2, where r stands for row, c for column. See T2 and T3 examples of how to read the contingency tables for the two distinct types of corrections, change towards or away from a given AA. P-values are based on a 2-sided Fisher&#x02019;s exact test, the q-values were based on all signature p-values. We also list ranked AAs, based on the most informative AAs for our machine learning implementation of <italic>Regression</italic> (predicting IC<sub>50</sub> values from sequences, <xref rid="mmc1" ref-type="supplementary-material">Table S4</xref>) and <italic>Classification</italic> (predicting positive/negative IC<sub>50</sub> values from sequences, <xref rid="mmc1" ref-type="supplementary-material">Table S5</xref>). These are listed by rank of importance, followed by the HXB2 position and the amino acid, or a dash if a deletion is important. The next columns show results from other signature analysis papers, including just the associations that were directly reported and readily retrieved from the primary publications. The association is listed alongside signature amino acid we have identified when possible. From West et&#x000a0;al. (<xref rid="bib86" ref-type="bibr">West et&#x000a0;al., 2013</xref>) we report associations given as the antibody name, the amino acid association, and the position. Chuang et&#x000a0;al. summarizes the published NEP predictions for the 10 highest rank scores (<xref rid="bib16" ref-type="bibr">Chuang et&#x000a0;al., 2013</xref>, <xref rid="bib17" ref-type="bibr">Chuang et&#x000a0;al., 2014</xref>). Hepler et&#x000a0;al. (<xref rid="bib40" ref-type="bibr">Hepler et&#x000a0;al., 2014</xref>) associations are from the primary publication using IDEPI. Ferguson et&#x000a0;al.&#x02019;s results are listed as compressed sensing results (given as amino acid and position), ensemble support including mutual information (given as yes or no) and experimental support (given as yes or ND for not done).</p><p>E. V3 bNAb phylogenetically corrected signatures and statistical support<bold>.</bold> V3 bNAbs contacts are highlighted in blue, based on two Env bound structures: PGT128 (301, 303, 304, 323-327, 332) (<xref rid="bib68" ref-type="bibr">Pejchal et&#x000a0;al., 2011</xref>) and PGT135 (295, 301, 330, 332, 339, 373, 384, 386, 389, 392, 409, 415, 417-419). The bNAb 2G12 is also included here, even though its epitope is very distinct from the other antibodies included this table.</p><p>F. V2 bNAb phylogenetically corrected signatures and statistical support. V2 bNAbs contacts are highlighted in green, based on structural contacts for PG9 (<xref rid="bib56" ref-type="bibr">McLellan et&#x000a0;al., 2011</xref>) (contact signatures are: PNGS at N156-158, PNGS at N160-162, 165, 167-171, 173).</p><p>G. CD4bs bNAb phylogenetically corrected signatures and statistical support. Representative CD4bs bNAbs contacts are highlighted in lavender and are based on an inclusive summary of structural contacts defined for CD4 and CD4bs bNAbs. These contact regions include the following HXB2 positions: V1 proximal: 97-99, 122-129, 196-198, 207, loop D: 275-283, 308, 318, CD4 binding loop: 364-374, beta20/21: 425-432, beta23: 455-459, V5 hypervariable region 460-465, beta 24: 466-477. Sites within the V5 hypervariable region are not included in the signature analysis, even though they can interact directly with the CD4bs bNAbs, due to alignment uncertainty. Contacts regions for CD4bs bNAbs and CD4 were defined based on the following data: CD4 contacts (<xref rid="bib90" ref-type="bibr">Wu et&#x000a0;al., 2011</xref>, <xref rid="bib92" ref-type="bibr">Zhou et&#x000a0;al., 2010</xref>): 124-127, 196-198, 279-283, 365-370, 374, 425-432, 455-461, 469-477; VRC01 contacts (<xref rid="bib90" ref-type="bibr">Wu et&#x000a0;al., 2011</xref>, <xref rid="bib92" ref-type="bibr">Zhou et&#x000a0;al., 2010</xref>): 97, 122, 276, 278-283, 365-368, 371, 427-430, 455-476; IgG1b12 contacts (<xref rid="bib100" ref-type="bibr">Zhou et&#x000a0;al., 2007</xref>): 267, 268, 280, 281, 364-373, 395, 397, 417-419, 430-432, 453-458; NIH45-46 contacts: 97-99, 102, 122-124, 127-128, 276, 427, 430-432, 455-480; 3BNC117 contacts (<xref rid="bib98" ref-type="bibr">Scheid et&#x000a0;al., 2016</xref>): 124, 198, 207, 275-276, 278-282, 308, 318, 365-368, 371, 428-430, 455-462, 469, 473.</p><p>H<bold>.</bold> MPER bNAb phylogenetically corrected signatures and statistical support. 2F5 and other MPER antibodies bind to distinct regions. The 2F5 epitope is focused on the sites 662-668 (the HXB2 sequence ELDKWAS) (<xref rid="bib97" ref-type="bibr">Ofek et&#x000a0;al., 2004</xref>) and is highlighted in dark brown. 4E10 is focused on the sites 671-676 (NWFDIT) (<xref rid="bib95" ref-type="bibr">Cardoso et&#x000a0;al., 2005</xref>) and the broader more potent 10E8 extends further out, 671-683, NWFDISNWLWYIK with contacts including positions 671-673 and 676 (<xref rid="bib44" ref-type="bibr">Huang et&#x000a0;al., 2012</xref>). The DH511 lineage binds to an epitope similar to 10E8 (<xref rid="bib87" ref-type="bibr">Williams et&#x000a0;al., 2017</xref>). The 10E8/4E10/DH511 epitopes are highlighted in light brown.</p><p>I-M. Amino acid associations with bNAb sensitivity in sites of interest, organized by site<bold>.</bold></p><p>Separate tabs are provided for each bNAb class studied (I-L). We include sites here after a hypothesis has been raised that a site is of interest: if a site is statistically significant after a phylogenetic correction, i<italic>.</italic>e<italic>.</italic> included in <xref rid="mmc1" ref-type="supplementary-material">Table S4</xref> for any antibody in a class, or if it is directly in a bNAb contact residue, it is considered of interest for the full bNAb class. Next, Fisher&#x02019;s test for associations of all amino acids at that site with a q&#x000a0;&#x0003c; 0.2 for all antibodies in that class are listed. &#x0201c;Table 1&#x0201d; (T1) is a contingency table for a simple Fisher&#x02019;s exact test based on the amino acid under consideration in all of the sequences in the set and their IC<sub>50</sub> breakdowns, with no phylogenetic correction applied. This table uses the same columns headings defined in <xref rid="mmc2" ref-type="supplementary-material">Table S3</xref> E-H, but the table rows are organized by HXB2 position instead of by antibody. An example of how to read the contingency table is provided in each data spreadsheet. We then list importance-ranked signatures based on our machine learning implementation for regression (levels of sensitivity, <xref rid="mmc1" ref-type="supplementary-material">Table S4</xref>) and classification (positive/negative <xref rid="mmc1" ref-type="supplementary-material">Table S5</xref>), followed by columns that show previously published signatures for antibodies in our study. The association is listed alongside signature sites we have identified, if the earlier finding is also supported by our analyses, or in a separate row if we did not find support for the reported association in our analyses.</p><p>I. Simple signatures associated with V3 bNAb sensitivity in sites deemed of interest. Contact residues are highlighted in blue.</p><p>J. Simple signatures associated with V2 bNAb sensitivity in sites deemed of interest. Contact residues are highlighted in green.</p><p>K. Simple signatures associated with CD4bs bNAb sensitivity in sites deemed of interest. Contact residues are highlighted in lavender.</p><p>L. Additional signatures associated with MPER bNAb sensitivity in sites deemed of interest.</p><p>2F5 Contact residues are highlighted in dark brown, other MPER antibody contacts in light brown.</p><p>M. Results of applying a Wilcoxon test to CD4bs antibodies from dataset 4. Our signature bioinformatics tool provides an option to use a Wilcoxon rank sum test to compare the IC<sub>50</sub> score distributions, in the presence or absence of a give amino acid at a given position, and we tested its performance for dataset 4. For most bNAb classes, this yielded fewer signatures and less significant results than the Fisher&#x02019;s exact test for the same data, but CD4bs bNAbs had exceptions listed here. This table includes only cases for which the Wilcoxon yielded comparable or lower p-values than Fishers, and so adds signatures to part C. The number of pseudoviruses with (AA) and without (AA) the signature amino acid, and the median value of the IC<sub>50</sub> data for that set of pseudoviruses, are noted for each antibody.</p><p>N-R. Hypervariable region characteristic signatures. Excel spread sheet, supporting <xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>B<bold>.</bold> The statistics of associations between of V1, V2, V4, and V5 hypervariable region characteristics and IC<sub>50</sub> scores for each antibody organized by antibody class. Separate tabs are provided for each bNAb class studied (N-Q); and tab R provides a key showing the boundaries of hypervariable regions relative to HXB2. Our analyses considered characteristics of the full-length variable loops, the more narrowly defined hypervariable segment (in bold lettering) that cannot be reliably aligned, and the sum of behaviors across both V1 and V2; we included 10 regions in all, in our search for correlates with bNAb potency. The characteristics of combined V1&#x000a0;+ V2 regions were often a stronger correlate of bNAb sensitivity than of either V1 or V2 considered in isolation. Only characteristics that had at least one association based on Kendall&#x02019;s tau with a q-value&#x000a0;&#x0003c; 0.2 are captured in this table; once that level of significance was found, the characteristic is considered of potential interest, and all associations between a characteristic and antibodies of the same class are shown. Dataset 3 (C clade) and dataset 4 (M group) are included here, as they are the largest datasets and best powered. If only the hypervariable region of a loop was used for the analysis, it is indicated by an &#x0201c;h&#x0201d;, for example V1 means the entire V1 loops was used, V1h means only the hypervariable region. If two highly related characteristics were identified as statistically of interest, like V1 and V1h, only the most significant relationship of the two was retained. The characteristics are: <italic>Charge</italic>, the net charge of the amino acids spanning the region considered (summing over each region such that an Arg, Lys and His contribute&#x000a0;+1, Glu and Asp -1); <italic>Length,</italic> the number of amino acids in the region based on the HXB2 boundaries; and <italic>Glycos,</italic> the number of PNGSs within the boundaries of the region under consideration. Kendall&#x02019;s tau was used to calculate p-values.</p><p>N. V loop and hypervariable region characteristics associated with V3 bNAb sensitivity. Excluding negative IC<sub>50</sub> responses enhanced correlations, so the impact of loop length on potency among just positive responders was more dramatic. This is likely because viruses are completely resistant when the PNGS at N332 is lost, regardless of loop characteristics. Thus, even viruses with favorable loop characteristics will be negative if the PNGS at N332 is absent, complicating resolution of other characteristics of importance.</p><p>O. V loop and hypervariable region characteristics associated with V2 bNAb sensitivity.</p><p>P. V loop and hypervariable region characteristics associated with CD4bs bNAb sensitivity.</p><p>Q. V loop and hypervariable region characteristics associated with MPER bNAb sensitivity</p><p>Increasing numbers of PNGS&#x02019;s in the V1 loop correlated with enhanced sensitivity to 10E8, and with other MPER bNAbs to a lesser extent. This was the only case where increasing the size of the variable region was associated with increased bNAb sensitivity.</p><p>R. Hypervariable region boundaries are relative to the HXB2 reference strain V loop sequences. Hypervariable regions are highlighted in bold and red and are subregions of the full variable region loops.</p></caption><media xlink:href="mmc2.xlsx"/></supplementary-material><supplementary-material content-type="local-data" id="mmc3"><caption><title>Table S6. Machine Learning Informative Feature Contributions, Related to Figure&#x000a0;4</title><p>This table presents ranked signature features that were among the top 10 most informative sites for different antibodies of different classes. It has four sections, one for each antibody class, and each section lists the most important signature features for Classification and Regression predictions for each antibody tested from dataset 4. On the right are summaries of the number of times recurrent features are found. Different shades highlight different V loop characteristics. Bold indicates sites that were repeatedly informative for a number of antibodies (at least 4/11 times for CD4bs bNAbs, 3/6 times for V2 bNAbs, 3/6 times for V3 bNAbs, and 2/3 for MPER bNAbs). Blue indicates signature positions within epitope contact regions, and black indicates positions outside the contact region. NxST N332 and NxST N160 indicate a PNGS. Clades were only rarely among the most informative data for prediction.</p></caption><media xlink:href="mmc3.xlsx"/></supplementary-material><supplementary-material content-type="local-data" id="mmc4"><caption><title>Document S2. Article plus Supplemental Information</title></caption><media xlink:href="mmc4.pdf"/></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgments</title><p>Supported by the <funding-source id="gs1">Bill &#x00026; Melinda Gates Foundation</funding-source> (OPP1032144, OPP1040741, OPP1032144, and OPP1169339), the <funding-source id="gs2">NIH</funding-source> (AI096040, AI100645, A1095985, AI124377, AI126603, AI128751, and AI129797), and the <funding-source id="gs3">Ragon Institute</funding-source> of MGH, MIT, and Harvard. We have no financial conflicts of interest. We thank Robert Bailer and Mark Louder, VRC, NIAID, for contributing large panel neutralization data. We thank Mark Connors, Lynn Morris, Penny Moore, Michel Nussenzweig, Michael Farzan, and Matthew Gardner for availability of antibodies and reagents; the HVTN Laboratory Program and Leonidas Stamatatos for envelope sequences; Nicholas Provine, Zi Han Kang, Alex Badamchi-Zadeh, Pablo Penaloza-MacMaster, Rafael Larocca, Sophia Rits-Vollach, Sandra Vertentes, and Helen DeCosta for generous assistance and advice; and Kelli Green and Hongmei Gao for their organizational efforts.</p><sec id="sec5"><title>Author Contributions</title><p id="p0380">Conceptualization, B.K., C.A.B., D.H.B., and D.C.M.; Software, H.Y., J.T., B.K., M.T., K.W., and P.H.; Writing, C.A.B., K.Y., B.K., and D.H.B.; Review &#x00026; Editing, J.T., G.H.L., B.H.H., K.W., J.P.M., E.F.K., M.S.S., D.C.M., B.F.H., and J.R.M.; Analysis, B.K., J.T., K.Y., E.E.G., K.W., M.T., P.H., C.A.B., D.H.B., and M.S.S.; Supervision, D.C.M., B.K., B.H.H., S.G., D.H.B., M.S.S., B.C., C.O., and K.E.S.; Bioinformatic Methodology, B.K., D.C.M., K.Y., and E.F.K.; Data Curation, J.P.M., K.Y., and G.H.L.; Immunological and Biochemical Assays, C.A.B., M.S.S., J.M.K., J.L.S., C.L.L., F.G., M.R., M.G.B., G.H.N., K.M., J.J.J., J.Z., C.O., H.P., C.C., J.P.N., K.E.S., and L.D.W.; Visualization, B.K., K.W., K.Y., and J.T.; Resources, N.D.-R., J.R.M., M.S.S., D.C.M., J.F.S., M.B., L.D.W., and B.F.H.; Funding Acquisition, D.C.M., D.H.B., B.F.H., and B.K.</p></sec><sec id="sec6"><title>Declaration of Interests</title><p id="p0385">The authors declare no competing interests. A provisional patent application for the vaccine technology has been filed by C.A.B., K.Y., D.H.B., and B.K.</p></sec></ack><fn-group><fn id="app1" fn-type="supplementary-material"><p id="p0390">Supplemental Information includes seven figures and seven tables and can be found with this article online at <ext-link ext-link-type="doi" xlink:href="10.1016/j.chom.2018.12.001" id="intref0165">https://doi.org/10.1016/j.chom.2018.12.001</ext-link>.</p></fn></fn-group></back></article>